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 I SUMMARY 
SUMMARY 
In recent years, affordable costs of next-generation sequencing technologies set the basis for 
the characterization of a multitude of cancer genomes. In doing so, scientists all over the 
world reconfirmed that cancer is a disease of the (epi)genome. The growing number of 
genetic abnormalities found in chromatin remodeling factors in various cancer entities 
produced evidence that aberrant chromatin modification plays an essential role in cancer 
initiation and progression.  
Besides numerous mutations of histone modifying factors in different cancer types, two 
recurrent mutations within the histone H3.3 coding gene H3F3A have been identified in about 
50% of pediatric glioblastoma. Both mutations result in amino acid substitutions at two critical 
residues of the histone tail of H3.3 (K27M or G34R/V). Since glioblastomas harboring one of 
these H3.3 mutations are characterized by a complex but stereotypic pattern of genetic and 
epigenetic alterations, the project presented here uses a variety of molecular techniques to 
study the functional mechanisms associated with both H3.3 mutations.  
By using confocal imaging of fluorescently labeled H3.3 mutants and genome-wide 
sequencing-based chromatin immunoprecipitation (ChIP-Seq) of ectopically expressed H3.3 
mutants, it was demonstrated that deposition and incorporation of histone H3.3 into 
chromatin is not affected by the mutations. Furthermore, experiments with different cell lines, 
which were genetically modified to stably overexpress mutant H3.3, provide evidence that  
(at least) some of the genome-wide changes that were originally found in H3.3 mutated 
glioblastomas, can be faithfully recapitulated in vitro.   
The investigation of several epigenetic marks by Western blot analysis and 
immunohistochemistry identified a strong dominant negative effect of the K27M mutant H3.3 
protein, which causes global reduction of the key epigenetic mark H3K27me3. Moreover, this 
epigenetic alteration found in primary tumors, was induced in vitro by overexpression of 
K27M mutant H3.3 in different cell lines.   
By using mass spectrometry to dissect the pattern of posttranslational modifications (PTM) at 
the histone tail of G34R mutant H3.3, a new PTM has been identified, namely dimethylation 
of arginine 34. Furthermore, first evidence is provided that this new PTM is causative for the 
downregulation of K36 trimethylation at G34R mutant H3.3. 
Finally, overexpression of mutant H3.3 in the brain of neonatal mice was performed by 
retroviral gene transfer. In doing so, this study aims at the elucidation of the in vivo 
tumorigenic potential of both histone H3.3 mutations alone or in combination with impaired 
TP53 function.  
In summary, the findings of this thesis provide novel insights into the comprehensive 
epigenetic changes caused by mutant histone H3.3 in pediatric GBMs. These results might 
provide the basis for the development of novel therapeutic strategies targeting the epigenetic 
changes induced by H3.3 mutations, which have been identified recently in nearly half of the 
tumors in children suffering from this devastating brain tumor.   
 II ZUSAMMENFASSUNG 
ZUSAMMENFASSUNG 
In den vergangenen Jahren bildeten die fallenden Kosten für die Hochdurchsatzsequenzierung 
die Grundlage für die genetische Analyse einer Vielzahl von Tumorgenomen. Hierdurch konnten 
Forscher weltweit bestätigen, dass es sich bei Krebs um eine Erkrankung des (Epi)Genoms 
handelt. In unterschiedlichen Krebsarten wurden vermehrt genetische Defekte in Chromatin-
modifizierenden Faktoren gefunden, die den Beweis erbrachten, dass Veränderungen der 
Chromatinmodifizierung eine entscheidende Rolle bei der Krebsentstehung und beim 
Fortschreiten der Erkrankung spielen.  
Neben der Identifizierung einer Vielzahl von Mutationen in Histon-modifizierenden Faktoren in 
unterschiedlichen Krebsentitäten, wurden in pädiatrischen Glioblastomen (pedGBMs) zwei 
rekurrente Mutationen im Histon H3.3 kodierenden Gen H3F3A entdeckt. Beide Mutationen 
führen zum Austausch von Aminosäuren an wichtigen Positionen des Histonproteins (K27M bzw. 
G34R/V). Glioblastome, die eine dieser Mutationen tragen, zeichnen sich durch ein komplexes 
aber sehr charakteristisches Muster an genetischen und epigenetischen Veränderungen aus. Um 
beide H3.3 Mutationen funktionell zu charakterisieren, wurde eine Vielzahl von molekularen 
Untersuchungsmethoden verwendet. 
Unter Verwendung konfokaler Mikroskopie Flurochrom-gekoppelter H3.3 Mutanten und Genom-
weiten Sequenzierdaten einer Chromatin Immunopräzipitation (ChIP-Seq) belegt diese Arbeit, 
dass die Inkorporation von Histon H3.3 in Chromatin durch keine der beiden Mutationen 
beeinträchtigt wird. In in vitro Experimenten wurden unterschiedlichen Zelllinien genetisch 
manipuliert, sodass sie mutiertes H3.3 überexprimieren. Die Ergebnisse zeigen, dass (zumindest) 
ein Teil der Genom-weiten Veränderungen, wie sie ursprünglich in H3.3 mutierten Glioblastomen 
gefunden wurden, im Zellkulturmodell rekapituliert werden.  
Die Untersuchung mehrerer epigenetischer Modifikationen durch Western Blot Analysen und 
Immunohistochemie identifizierte einen starken dominant-negativen Effekt des K27M mutierten 
H3.3 Proteins, welcher zu einer globalen Reduktion der H3K27me3 Expression führt. Diese 
epigenetische Veränderung in Primärtumoren konnte durch die Überexpression von K27M 
mutiertem H3.3 in mehreren Zelllinien in vitro nachgebildet werden.  
Massenspektrometrie wurde verwendet um posttranslationale Modifikationen (PTMs) am G34R 
mutierten Histon zu untersuchen. Das dadurch detektierte Dimethyl-Arginin 34 stellt eine bisher 
nicht beschriebene PTM dar. Darüber hinaus liefert diese Arbeit erste Hinweise dafür, dass diese 
neuartige PTM die H3K36 Trimethylierung an G34R mutiertem H3.3 negativ reguliert.  
Überdies wurden die Histon H3.3 Mutanten im Gehirn von neugeborenen Mäusen mittels 
retroviralen Gentransfers überexprimiert, um zu untersuchen, ob dies alleine oder in Kombination 
mit defektem TP53 Tumore induziert. 
Zusammenfassend gibt die vorliegende Arbeit neue Einblicke in die umfassenden epigenetischen 
Veränderungen, die durch H3.3 Mutationen in pädiatrischen GBMs hervorgerufen werden. Diese  
richtungsweisenden Ergebnisse könnten den ersten Schritt in der Entwicklung neuer Therapien 
zur Behandlung der durch H3.3 Mutationen verursachten epigenetischen Veränderungen 
bedeuten. Diese wurden kürzlich in nahezu der Hälfte aller Tumore in Kinder und Jugendlichen 
beschrieben, die an diesem in der Regel tödlich verlaufenden Hirntumor leiden.  
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 1 INTRODUCTION 
1 INTRODUCTION 
1.1 Cancer - A Disease of the (Epi)Genome 
Since the early 19th century, defects within the genetic information were suspected to cause 
cancer. At this time, Theodor Boveri and David von Hansemann described an abnormal 
number of chromosomes due to aberrant mitosis in cancer cells [2, 3]. Today, there is 
overwhelming evidence that cancer is a disease of the genome. Cancer is believed to start 
when a single cell in one part of the body has acquired the ability to uncontrolled cell 
proliferation. Although this might sound harmless, in worst case uncontrolled cell growth 
ends up in cancer related death, as it was the case for 7.6 million people worldwide, who 
died due to cancer in 2008 [4]. According to the World Health Organization (WHO), cancer is 
the leading cause of death all over the world, accounting for 13% of all deaths worldwide [5]. 
Current estimates assume that every day within the year 2013, approximately 1600 people 
will die due to cancer in the US [6].  
Cancer is a genetic disease which develops in a multistep process. At the end of this process 
a cell has acquired several properties, which allow for tumor growth and progression. Within 
recent years, our knowledge about these malignant properties, which are essential to drive 
cancerous transformation, increased rapidly. Some years ago, six malignant properties, also 
known as the hallmarks of cancer, have been reported to be necessary to transform normal 
cells into cancerous ones [7]. In order to become malignant, a tumor cell has to acquire the 
capability to escape programmed cell death (apoptosis), replicate without limit, be 
independent of exogenous growth signals and resistant to anti-proliferative signals. 
Moreover, the capability to grow into healthy neighboring tissues by invasion or metastasis 
and the ability to supply the developing tumor with nutrients by the growth of new blood 
vessels (angiogenesis) enhances mortality of cancer enormously [7]. Today, it is well 
accepted that cells have to obtain additional properties to become malignant. These include 
the potential to use different metabolic pathways to produce all classes of macromolecules. 
This hallmark of cancer is based on the observation that cancer cells show fundamental 
differences in metabolic pathways to produce energy, a phenomenon called Warburg effect 
[8]. Furthermore cancer cells have to evade immune destruction but might benefit from the 
tumor supportive effect of immune cells. Last but not least, an essential hallmark of cancer is 
the development of genome instability [9].  
Genomic instability is a crucial hallmark of cancer as it promotes the acquisition of all other 
malignant properties described above via accumulation of numerous genomic aberrations 
and/or mutations. On the one hand, these genomic changes target genes which in principal 
have the ability to promote cancer development (proto-oncogenes). When activated, e.g. by 
mutation, these genes are called oncogenes. On the other hand, both alleles of genes 
named tumor suppressors have to be inactivated to drive a cell into cancerous development. 
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Since new DNA sequencing technologies provide the possibility to decipher the mutational 
landscape of tumor genomes in a fast and cost effective way, the number of mutations 
identified in both of these classes of cancer related genes, oncogenes and tumor suppressor 
genes, has increased rapidly. As an example, the detailed analysis of hundreds of genomes 
of medulloblastoma, which represents one of the most devastating brain tumors in childhood, 
led to the identification of several new oncogenes and tumor suppressor genes, which have 
been found to be recurrently mutated [10, 11]. One of the most comprehensive cancer 
sequencing efforts worldwide has recently been launched by the International Cancer 
Genome Consortium (ICGC), which initiated the genomic analysis of more than 25,000 tumor 
genomes from 50 different cancer entities [12]. The results of this international large scale 
sequencing effort will decisively improve our knowledge of the genetic disease named 
cancer.     
The past decade of cancer research has underlined the fact that cancer is not only a disease 
of the genome but also a disease of the epigenome. The epigenome is defined as cellular 
information, other than the DNA sequence itself, which is heritable through cell division [13]. 
Alterations within the epigenome are an alternative/additional mechanism to promote 
tumorigenesis. These alterations include the activation and inactivation of oncogenes or 
tumor suppressor genes, respectively, by DNA methylation and the regulation of DNA 
accessibility by altered chromatin structure via histone modifications [14]. In general, the 
cancer genome has been found to show global loss of DNA methylation (hypomethylation) 
which is complemented by specific genomic regions displaying aberrantly high DNA 
methylation (hypermethylation) [15, 16]. Basically, regions of DNA hypomethylation are 
associated with activated gene transcription, while genes located within hypermethylated 
regions of the genome are transcriptionally downregulated. Abnormal histone modifications 
in cancer change the overall structure of chromatin leading to a more open or condensed 
nucleosome configuration which allows or inhibits gene transcription, respectively. Epigenetic 
(in)activation of cancer related genes is assumed to be at least as frequent as mutational 
events [17]. Therefore, the sequencing results of each of the cancer genomes coordinated by 
the ICGC are strongly recommended to be complemented with genome-wide information on 
DNA methylation [12].   
Basically, every cell in the human body can undergo malignant transformation. However, 
some cells/tissues are much more susceptible to malignant transformation. This is mainly 
due to differences in exposure to exogenous stimuli (carcinogens) like irradiation, tobacco, 
alcohol or diet. Tissues, which are exposed to these carcinogens like skin, lung or colon are 
much more prone to develop cancer. Variable incidence rates of nearly all cancer types are 
mainly linked to environmental risk factors including behavioral, geographical and cultural 
differences [18]. Unlike many cancers in adults, childhood cancers are not linked to 
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environmental risk factors, as they arise sporadically, as a consequence of developmental 
defects or due to heritable causes. As for many diseases, gender is an essential factor 
influencing the development and prognosis of cancers. It has been shown that for the 
majority of different tumor entities including brain tumors, the overall incidence and mortality 
rates among males was significantly higher than in females [19]. In general, breast cancer is 
the most frequent and deadly cancer in females (23% of all diagnosed cancer cases resulting 
in 14% of total cancer deaths), while lung cancer is the most commonly diagnosed cancer 
type and most deadly entity in males (17% of all cancer cases resulting in 23% of total 
cancer deaths) [4].  
One of the most outstanding factors influencing the development of cancer is age, as almost 
all cancer incidence rates rise dramatically with age. However, brain tumors in infants and 
children are frequent and the second most common cause of death in this age group, 
surpassed only by traffic accidents.  
 
1.2 Childhood Brain Tumors 
More than 7% of the 300,000 individuals that were diagnosed with a primary brain tumor in 
the United States between 2004 and 2008 were younger than 20 years [20]. In this age 
group, tumors of the central nervous system (CNS) are the second most common 
malignancy after leukemia. Although incidence rates of leukemia are much higher, solid 
malignancies of the brain are the leading cause of cancer related mortality in childhood. This 
is mainly attributed to recent advances in leukemia treatment including precise risk 
stratification and personalized therapy, which have pushed the cure rate for some leukemias 
like acute lymphoblastic leukemia (ALL) in children and adolescents to more than 90% [21]. 
In comparison, advances in diagnosis and treatment of solid malignancies of the brain did 
not keep pace. Just nowadays, as researchers continuously unravel the molecular basis of 
childhood brain tumors, new treatment protocols, adapted to the needs and specific features 
of brain tumors in children, find their way into clinics.   
Given the fact that brain tumors of childhood and adolescence differ substantially from their 
adult counterparts, there is a desperate need of adapted diagnostic algorithms and treatment 
protocols for brain tumors in young patients. A subset of brain tumors, called embryonal 
tumors, can be found almost exclusively in children. These embryonal CNS tumors develop 
during intrauterine or early postnatal development due to dysregulation of signaling pathways 
crucial for normal CNS development [22]. In addition, genetic disorders, which are known to 
predispose children to develop a brain tumor, are found in about 10% of all pediatric brain 
tumor patients [23]. Genetic disorders associated with a higher risk to develop a brain tumor 
include Li-Fraumeni syndrome, characterized by mutations within the tumor suppressor gene 
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coding for p53 (TP53), Gorlin syndrome (PTCH1 or SUFU), Turcot syndrome (APC) and 
Neurofibromatosis type 1/2 (NF1/NF2) [24-27]. Most brain tumors, however, originate 
sporadically with notable differences between children and adults. Some brain tumors like 
benign gliomas are much more frequent in young patients, while highly malignant gliomas 
predominate in adult patients. In addition, pediatric brain malignancies often develop in the 
hindbrain, whereas hemispheric tumors dominate in adulthood. Consequently, approximately 
50% of all pediatric brain tumors arise infratentorially in the posterior fossa [28]. While being 
histopathologically indistinguishable, tumors of the same entity also dramatically differ in 
several genetic and epigenetic features between children and adults [29]. This includes the 
frequency of genomic aberrations such as hot spot mutations, which has been shown to be 
significantly higher in adult medulloblastoma compared to subgroup-matched tumors of 
pediatric patients [11].  
The main part of the thesis presented here deals with the functional consequences of histone 
H3.3 mutations, which represent a genetic alteration exclusively found in high grade gliomas 
of pediatric and adolescent patients [30]. Considering all aforementioned differences 
between pediatric and adult brain tumors, it is not surprising that current treatment protocols 
of brain tumors in childhood have to be adapted specifically to their characteristics. 
Additionally, treatment of pediatric brain tumors always faces the problem that the developing 
brain is highly vulnerable to aggressive treatment options, in particular radiotherapy [31]. This 
has led to limitations of radiotherapy usage in very young children (below 4 years of age), 
who have to be treated by postoperative chemotherapy alone [32]. In young patients quality 
of survival is of special importance since these patients have to live the rest of their life with 
all treatment-induced cognitive deficits. 
 
1.3 Glial Tumors 
The most common category of brain tumors diagnosed in children are tumors of glial origin 
(glioma). These tumors account for 53% of all brain tumors in very young patients  
(0-14 years) and 38% in adolescent patients (15-19 years) [20]. Gliomas represent the most 
frequent type of central nervous system neoplasms. In Europe and the United States 77,000 
new cases are diagnosed every year [33]. For almost a century, gliomas have been 
classified according to histological features, which resemble features of normal glial cells 
[34]. Thus, gliomas are classified into one of the three main groups: astrocytomas 
(astrocytes), oligodendrogliomas (oligodendrocytes) or ependymomas (ependymal cells) 
[35]. Whether these cells represent indeed the respective tumor initiating cells, however, 
requires further investigation. All three main groups of gliomas are further subdivided by 
additional histologic features of the respective tumors (Figure 1).  
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Based on the grade of malignancy, gliomas are graded into one of the four World Health 
Organization (WHO) grades (grade I to grade IV) [36]. While benign grade I gliomas 
generally can be treated by surgery alone, grade II tumors are low-risk tumors which grow 
infiltrative and need to be treated with adjuvant therapy. Unlike in children, grade II gliomas in 
adults frequently progress to grade IV glioblastomas. Grade III gliomas show much higher 
proliferation rates and tend to progress into grade IV tumors, the most malignant form of 
glioma. A summary of the WHO glioma classification by cellular origin and grading is given in  
Figure 1. 
 
Figure 1. Classification of Glial Brain Tumors. Overview of histological subtypes and WHO grading 
of glial brain tumors based on the 2007 WHO brain tumor classification [36]. In addition, relative 
frequency of tumors of glial origin are shown based on the 2004-2008 report of the Central Brain 
Tumor Registry of the United States (CBTRUS) [20]. Percentages represent the relative distribution of 
the respective glioma subtype within the total number of 89,617 tumors diagnosed between 2004 and 
2008 in the US.  
 
 
The most common and most life threatening type of glioma are grade IV astrocytomas, also 
termed glioblastoma multiforme (GBM), which account for approximately 54% of all glial 
tumors [20].  
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1.3.1 Glioblastoma 
Glioblastoma multiforme (GBM; WHO grade IV astrocytoma) represents the most common 
and most lethal type of glioma in children and adults [36]. Every year, there are 3 to 5 newly 
diagnosed cases per 100,000 individuals [37]. Three years after diagnosis more than 95% of 
all glioblastoma patients have died from disease due to the aggressive clinical behavior of 
this brain tumor [38]. This dismal prognosis is mainly a consequence of the invasive growth 
of GBMs and the resistance to conventional treatment, including surgery, radio- and 
chemotherapy. The large majority of these tumors (> 90%) develop rapidly de novo (primary 
GBMs), while only a subset progress gradually from grade II/grade III glioma within 5 to 15 
years and are therefore also referred to as secondary glioblastoma [37]. Based on their 
histology, primary and secondary GBMs are indistinguishable, but substantial molecular 
differences including genetic aberrations and distinct gene expression profiles strongly 
suggest that primary and secondary GBMs represent different disease entities sharing a 
comparable fatal prognosis [39, 40]. 
GBMs mainly affect the adult population with a median age of 64 years at diagnosis.  
Yet, 3% of all childhood primary brain tumors are pediatric glioblastomas (pedGBMs)  
[20, 37]. Almost all children, diagnosed with a pedGBM, die due to this fatal brain tumor 
within the next 3 years. Like in adults, pedGBMs may develop within one of the two cerebral 
hemispheres (or other regions of the brain), but some pedGBMs affect the brain stem and 
are then named diffuse intrinsic pontine gliomas (DIPGs). These tumors, which are almost 
exclusively found in children, are unresectable and are characterized by an even inferior 
prognosis compared to their hemispheric counterparts. Histologically, pedGBMs are 
indistinguishable from adult GBMs but substantially differ from adult GBMs in their hallmark 
molecular and genetic features, which are of major biological and clinical significance. Like 
adult primary GBMs, pedGBMs develop de novo but numerous studies have shown that 
pedGBMs harbor recurrent genomic aberrations, gene expression and DNA methylation 
profiles distinct from their adult counterparts [29, 41, 42]. Due to these fundamental genetic 
and epigenetic differences, it became obvious that distinct biological pathways are 
responsible for gliomagenesis in adults and children. Low incidence rates in children and the 
consequential paucity of frozen pedGBM samples has been hindering efforts to establish 
new treatment protocols specifically for childhood GBMs. Therefore, standard therapy is 
currently mainly based on clinical experience in adults.  
 
1.3.2 The (Epi)Genome in Childhood Glioblastoma 
Compared to malignant glioma in adults, which are characterized by genomic instability and 
a complex series of genomic aberrations, pediatric glioblastoma display a much more limited 
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spectrum of genomic aberrations, including a subset of tumors with an almost stable 
karyotype and more favorable prognosis [29, 41]. The most frequent genomic aberrations 
found in pedGBMs are amplification of the PDGFRA locus (4q12) and deletions of 
CDKN2A/B (9p21) [29, 41]. Focal chromosomal gains or losses have been found to mainly 
perturb gene function within the p53, PI3K/RTK, and RB pathways [41, 43]. In addition, 
deletions of other well-known tumor suppressor genes (e.g. PTEN) or amplifications of 
oncogenes have been reported at much lower frequency than in adults, including 
amplifications of EGFR (epidermal growth factor receptor) at 7p12, which is a very common 
event in adult primary glioblastoma [41]. The same holds true for mutations of IDH1 and 
IDH2 (isocitrate dehydrogenase 1/2), which are present in more than 90% of adult secondary 
GBMs but are hardly found in pedGBMs [44]. Large scale genomic alterations of pedGBMs 
include gain of 1q, which is described to be a common event in other childhood cancers as 
well, including aggressive pediatric ependymoma [45]. Notably, besides high PDGFRA 
expression due to gene amplification, aberrant PDGF signaling has been reported in a high 
proportion of pedGBMs, underscoring the importance of this signaling pathway in  
pedGBM [46].      
Recently, we and others identified a high frequency of pedGBMs harboring mutations within 
the H3.3/ATRX/DAXX chromatin remodeling pathway [30]. Two recurrent mutations within 
the H3F3A gene, encoding the replication independent replacement histone H3.3, were 
found in about 50% of pedGBMs [30, 47]. These mutations state the first described recurrent 
mutations within any of the highly conserved human histone genes. The first H3F3A mutation 
affects the codon for lysine 27 (K27) of H3.3, which was always found to be substituted by a 
methionine (K27M). The same mutation was found in DIPGs at a very high frequency, and at 
a lower frequency within the gene HIST1H3A, coding for the canonical histone H3.1 [47]. The 
second mutation leads to the replacement of glycine 34 (G34) by an arginine (R34R) and in 
some rare cases by a valine (G34V) [30, 47]. Interestingly, both mutations were also 
significantly associated with clinical parameters such as patient age or tumor location. While 
patients suffering from a K27M mutated pedGBM tend to be younger (median age 10.5 
years), G34R mutated tumors develop in adolescent patients/young adults with a median 
age of 18 years [48]. Furthermore, most of the K27M mutated tumors are midline tumors 
affecting the thalamus, brain stem or pons and are therefore commonly found in DIPGs [47, 
49]. In contrast, pedGBMs with G34R mutations are located within one of the two cerebral 
hemispheres [48].     
In a subsequent analysis, we were able to demonstrate that H3.3 mutated pedGBMs not only 
exhibit a distinct gene expression profile, but are also characterized by mutation specific 
genome-wide DNA methylation patterns [48]. Based on their methylome, pedGBMs can be 
subdivided into 5 different subgroups: All pedGBMs lacking H3F3A or IDH1 mutations either 
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belong to a group with high frequency of PDGFR amplifications (receptor tyrosine kinase 1 
group (RTK1_PDGFR)) or the so-called mesenchymal group, which mainly consists of 
tumors with a mesenchymal gene expression signature. All other pedGBMs can be 
subdivided into three subgroups, which are tightly correlated with mutations of IDH1 or 
H3F3A, that have been shown to be mutually exclusive. The methylome of IDH1 mutated 
tumors is very distinct from any other methylation profile as it is characterized by global DNA 
hypermethylation. IDH1 mutations are gain-of-function mutations, which have been shown to 
increase the intracellular level of the onco-metabolite 2-hydroxyglutatrate, a potent inhibitor 
of histone lysine demethylases and DNA methylases [50, 51]. The association of IDH1 
mutations and global DNA hypermethylation, which is predominantly found in adult GBMs, is 
also known as the Glioma CpG island methylator phenotype (G-CIMP) [52]. In addition, 
tumors harboring either K27M or G34R mutations of H3F3A also form a separate DNA 
methylation cluster each, with G34R mutated tumors displaying global DNA hypomethylation, 
which is predominantly affecting subtelomeric regions [48]. According to the CpG island 
methylator phenotype in IDH1 mutated GBMs, this hypomethylated pattern of G34R mutated 
pedGBMs was named CHOP (CpG hypomethylator phenotype).  
Differences have also been identified when correlating patient survival of all three mutation-
defined subgroups. As already reported for adult GBMs, IDH1 mutated pedGBMs are 
characterized by a slightly more favorable prognosis compared to their non-mutated 
counterparts. While patients suffering from a G34R mutated tumor are doing significantly 
better than H3F3A wildtype tumors, patients with K27M mutated tumors tend to do even 
worse without reaching statistical significance [48, 49].         
By applying an integrated analysis combining DNA methylation and gene expression data, 
our laboratory identified marker genes, which show differential methylation and expression 
within the described subgroups. A region of the FOXG1 (forkhead box protein 1) promoter 
was found to be specifically hypermethylated in K27M mutated pedGBMs, leading to loss of 
FOXG1 gene expression in K27M mutated tumors. The promoter of the two oligodendrocyte 
lineage marker genes OLIG1 and OLIG2 displayed concerted hypermethylation exclusively 
in G34R mutated pedGBMs, resulting in abolished OLIG1/2 gene expression. Hence, protein 
expression of OLIG1/2 and FOXG1 analyzed by immunohistochemistry (IHC) can be used as 
a surrogate marker to identify H3.3 mutated pedGBMs [48].  
In summary, more than 50% of pediatric high grade gliomas are characterized by recurrent 
genetic mutations of H3F3A and IDH1, which have been shown to directly impact the 
epigenome including the methylation of DNA and histone proteins. In addition, mutations 
within the genes coding for the two H3.3 specific histone chaperones ATRX (a-
thalassaemia/mental retardation syndrome X-linked) and DAXX (death-domain associated 
protein) were identified in 31% of all pedGBMs, including 100% of G34R mutated tumors and 
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approximately 67% of K27M mutants. Both, ATRX and DAXX, are essential components of 
the complex mediating H3.3 incorporation at pericentric heterochromatin and at telomeres. 
Loss of function mutations of ATRX have recently been proven to be associated with 
alternative lengthening of telomeres (ALT), a phenomenon which is significantly associated 
with G34R mutated pedGBMs [30, 53]. The potential link between global DNA 
hypomethylation at subtelomeric regions detected in G34R mutated pedGBMs and the 
existence of the ALT phenotype in these tumors requires further elucidation. The presence of 
ALT has been best explained in pedGBMs having simultaneous mutations within H3F3A, 
ATRX and the tumor suppressor gene TP53 [30]. Mutations of TP53 are reported to exist in 
all G34R mutated pedGBMs and about 67% of K27M mutant tumors. In adults, ATRX 
alterations are frequently found together with IDH1/2 and TP53 mutations in astrocytic 
tumors across all WHO grades [54].  
The high frequency of mutations directly interfering with epigenetic integrity together with the 
comparably low number of other genetic alterations commonly found in adult GBMs once 
more indicate that pedGBMs develop differently from adult GBMs. There is growing evidence 
that pedGBMs are primarily driven by genetic alterations resulting in defective epigenetic 
regulation. 
 
1.4 The Structure of Chromatin 
Within the eukaryotic cell nucleus, genetic information is organized in structures, called 
chromosomes, which allow enormous compaction of the entire hereditary information. Each 
of these chromosomes consists of a single DNA molecule, which is wrapped around highly 
conserved nucleoprotein complexes. This complex of DNA and proteins is called chromatin 
with nucleosomes being the repeating unit of this structure. In more detail, nucleosomes are 
composed of 146 base pairs of DNA wrapped around an octamer of the four core histones 
H2A, H2B, H3 and H4 [55, 56]. During nucleosome assembly, two pairs of H3-H4 
heterodimers form a heterotetramer, which is deposited onto DNA. Afterwards, a 
heterotetramer of two H2A-H2B pairs is added to complete the nucleosomal octamer [57]. 
Packaging of DNA around histone octamers leads to a chromatin fiber of about 10 nm in 
diameter [58]. This conformation represents the first packaging level of genomic information, 
which is mediated by intra- as well as internucleosomal interactions. A higher order of 
compaction is achieved by the presence of the linker histone H1, which is located between 
the nucleosomes at the DNA entry and exit sites [59]. Histone H1 allows the establishing of a 
more condensed chromatin fiber, which was formerly known as the 30 nm fiber [60, 61]. The 
existence of this 30 nm fiber in vivo is not supported by more recent data [62, 63]. Fiber-fiber 
interactions, which are regulated by structural components of the nucleosomes themselves 
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(internucleosomal) as well as additional architectural chromatin proteins (non-histone 
proteins) allow further condensation into a higher-order chromatin structure [64, 65].  
A schematic representation of chromatin and its different organization levels is given in 
Figure 2. 
The binding of architectural chromatin proteins like the methyl-CpG-binding protein 2 
(MECP2) or heterochromatin protein HP1 are substantially affected by the pattern of 
posttranslational modifications (PTMs) of the histone proteins or the exchange of histone 
variants. Besides the basic function of chromatin in storage and organization of the entire 
genetic information, it also provides the basis for substantial processes where the genetic 
information must be accessible such as during DNA replication, DNA repair or gene 
transcription. Overall, histone proteins are key players in the regulation of DNA accessibility.  
In 1910 Albrecht Kossel was awarded the Nobel Prize in Physiology and Medicine, for his 
pioneering work, describing histones as the major protein component of cellular nuclei 
(Kossel 1884). Histones are small proteins with a length of 102 (histone H4) to 135 (histone 
H3) amino acids. Due to a high content of the two basic amino acids arginine (R) and  
lysine (K), histones are overall positively charged. This characteristic facilitates interactions 
with the negatively charged DNA backbone. Histones are among the evolutionarily most 
conserved proteins and consist mainly of two important parts: A carboxy-terminal  
(C-terminal) histone fold, which forms the nucleosome scaffold, and a comparably short 
amino-terminal (N-terminal) tail, which protrudes outward from the nucleosome [66]. 
The carboxy-terminal histone fold domain forms the biggest part of the histone protein 
(approximately 75%). It shares low sequence homology with other core histones, but a 
common motif of tertiary structure, which is made up of three helices separated by short loop 
and ß strand structures [67]. These helices are responsible for the pairing of 2 heterodimers 
of H3-H4 or H2A-H2B during nucleosome assembly [55]. Mutations within the domain 
promoting the association of two H3-H4 pairs have been shown to interfere with nucleosomal 
incorporation by formation of aberrant histone interactions [68].  
The flexible amino-terminal tail of all core histone proteins is highly conserved and varies in 
length from 13 (histone H2A) to 42 (histone H3) amino acids. While the major part of histone 
proteins forms a globular structure, the histone tails protrude from the nucleosome core 
particle. This exposed position ensures its accessibility to enzymes establishing 
posttranslational modifications, which directly affect chromatin structure.   
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Figure 2. Chromatin Structure. Schematic representation of chromatin and its different organization 
levels. Genomic DNA is wrapped around a nucleosome comprising the histone octamer with a 
diameter of approximately 10 nm. Further chromatin condensation is achieved by addition of the linker 
histone H1, which stabilizes the more condensed chromatin fiber with a diameter of approximately  
30 nm. High order chromatin structures built up the condensed (mitotic) chromosome, which consists 
of the two sister chromatids.  
 
 
1.4.1 The Histone Code  
For about half a decade it has been known that residues within the amino-terminal tail of 
histones can be subjected to posttranslational modifications (PTMs) [69]. Since then, the 
number of different modifications, which have been found at the histone tail of all core 
histones H2A, H2B, H3 and H4, has rapidly increased. Today, histone methylation, 
phosphorylation and acetylation have been studied extensively but the list of known PTMs 
targeting the histone tail also includes ubiquitination, sumoylation, biotinylation, ADP 
ribosylation, glycosylation, carbonylation and others [70-79]. Just recently, a mass 
spectrometry-based study reported on the identification of 67 new PTMs including 
crotonylation of lysine residues, which have been found at the amino-terminal tail and within 
the histone fold domain of all 4 core histones [80]. Depending on type and location of PTMs, 
the combination of these chemical modifications builds up the so called histone code, which 
directly regulates chromatin structure and gene transcription [81-83]. These highly dynamic 
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changes of the chromatin template take place during many fundamental cellular processes 
such as gene transcription or DNA replication. Moreover, chromatin organization and 
modifications of specialized histone variants like H2AX are essential to ensure genome 
integrity during DNA damage response (DDR) [84].    
According to their association with chromatin structure and gene expression, PTMs can be 
classified as heterochromatic/repressive or euchromatic/activating histone marks. Some of 
the extensively studied repressive histone modifications are the trimethylation of histone H3 
at lysine 9 (H3K9me3) or lysine 27 (H3K27me3) [85]. Other PTMs like H3K4me3 or 
H3K36me3 are associated with open chromatin and active gene expression [86]. Besides 
this simplified view on PTMs and their association with either active or inactive transcription, 
it has been shown that the precise enrichment pattern of a PTM at a gene of interest should 
be considered as well, as it might be linked to distinct regulatory consequences. Depending 
on the exact enrichment profile, H3K27me3, considered to be a repressive histone mark, has 
also been found at actively transcribed genes [87]. Moreover, several studies on embryonic 
stem cells and differentiated T-cells report on the existence of so-called bivalent domains 
within the genome, which are marked simultaneously by activating and repressive marks 
(e.g. H3K27me3 and H3K4me3) [88, 89]. Since these bivalent domains have been found at 
developmental genes, their existence has been suggested to play a fundamental role in cell 
differentiation.  
In general, the highly dynamic state of chromatin has to be tightly regulated by antagonizing 
chromatin modifying enzymes. These enzymes are responsible for the introduction 
(epigenetic writers) or removal (epigenetic erasers) of modifications in a site-specific manner. 
Methylation of lysine residues is mediated by enzymes known as histone methyltransferases 
(HMTs). Two families of HMTs have been described, which catalyze the addition of methyl 
groups from S-adenosylmethionine to histone proteins. Both families are characterized by 
distinct protein domains catalyzing the methylation: The SET-domain containing HMTs and 
enzymes harboring a DOT1-domain [70].  Histone demethylases (HDMs) like the lysine-k 
specific demethylase 1A (KDM1A or LSD1) have been identified as epigenetic erasers 
removing methyl groups from histones [90]. While lysine residues are subjected to mono-, di- 
and trimethylation, methylation of the second basic amino acid arginine (R) includes only 
mono- and dimethylation, but with the differentiation of symmetric dimethylarginines (SDMA) 
and asymmetric dimethylarginines (ADMA). Arginine methylation is performed by a separate 
family of enzymes called protein arginine methyltransferases (PRMTs). This family includes 
11 members, which catalyze either the reaction producing symmetrically or asymmetrically 
methylated arginines [71, 91]. Antagonizing enzymes, mediating the removal of methyl 
groups from arginines, are for instance the jumonji-domain containing protein 6 (JMJD6) [92]. 
For the sake of completeness it should be noted that the third basic amino acid histidine is 
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known to become monomethylated but this PTM has not been characterized in more detail to 
date [93].        
Lysine residues of histone proteins are not only subjected to posttranslational methylation but 
also acetylation, which is accomplished by epigenetic writers called histone 
acetyltransferases (HATs). These enzymes uniquely use acetyl coenzyme-a as the donor to 
transfer acetyl groups to the lysine residues of histones. The opposing activity is governed by 
histone deacetylases (HDACs), which are important for the regulation of dynamic levels of 
lysine acetylation.            
In addition to these modifications of the basic amino acids within the histone tail, there are 
also modifications of other amino acids, such as phosphorylation of the polar amino acids 
serine and threonine. Histone phosphorylation takes place at all known histones including all 
4 core histones and the linker histone H1 and is mediated by a large variety of different 
kinases [94]. As other PTMs, histone phosphorylation directly affects the dynamics of other 
key PTMs. One of the most intensively studied histone phosphorylation events is that of 
serine 10 at the tail of histone H3 (H3S10p), which affects other modifications including 
methylation of H3K9 in close vicinity [95]. Serine/threonine-specific phosphatases are 
described as the epigenetic erasers of this PTM.  
In order to be catalytically active in vivo, all aforementioned epigenetic writers and erasers 
are dependent on incorporation into large multiprotein complexes. Other subunits of these 
complexes ensure proper nucleosomal association or modulation of the catalytic activity. 
One of these multiprotein complexes is the Polycomb repressive complex 2 (PRC2), which 
contains the H3K27 specific histone methyltransferase enhancer of zeste 2 (EZH2) [96]. 
Besides its catalytically active subunit EZH2, PRC2 comprises additional core subunits, 
including suppressor of zetse 12 (SUZ12), retinoblastoma-binding protein p48 (RBAP48) and 
embryonic ectoderm development (EED). While SUZ12 and RBAP48 are involved in 
targeting the complex to nucleosomes, EED is able to enhance the catalytic activity of EZH2 
[97]. Loss of one of these subunits such as SUZ12 leads to genome-wide alterations in 
H3K27me3 levels [98]. The presence of activating PTMs such as H3K4me3 is known to 
inhibit PRC2 function [97]. Interestingly, recent work shows that the PRC2 subunits EED and 
SUZ12 are also able to bind to trimethylated lysine 27 at histone H3, leading to a model for 
propagation of the repressive histone mark H3K27me3 in proliferating cells [99, 100]. The 
role of the EZH2 homolog EZH1 in the establishment and maintenance of the H3K27me3 
mark (particularly in stem cells) is currently being intensively studied [101, 102]. A summary 
of PTM of the amino-terminal tail of histone H3.3 is given in Figure 3. 
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Figure 3. Posttranslational Modifications of the amino-terminal Histone H3.3 Tail. Occurrence 
and localization of several PTMs at the tail of histone H3.3 (amino acid position 1-40). This overview 
includes mono- and dimethylation of lysine (K) and arginine (R) residues, trimethylation of lysines, 
acetylation of lysines and phosphorylation of serine (S) and tyrosine (T) residues.  
 
Although some PTMs per se such as acetylation of lysines are known to directly change the 
highly positive charge of histone tails and thereby its physicochemical properties, translation 
of the highly dynamic epigenetic code into cellular processes like gene transcription or DNA 
repair is mainly mediated by protein complexes called epigenetic readers [103]. These 
protein complexes harbor highly-conserved protein domains recognizing and binding to the 
temporal and spatial pattern of PTMs. Methylated lysine residues for example are recognized 
by numerous proteins harboring either a plant homeodomain (PHD), PWWP domain (named 
after the core amino acid sequence prolin-tryptophan-tryptophan-prolin), tudor domain or 
chromodomain (chromatin organization modifier) [104-106]. In contrast, the existence of a 
bromodomain (BRD) allows the binding to acetylated lysine residues [107]. The existence of 
proteins containing more than one of these reader domains further increases the level of 
complexity. Not surprisingly, epigenetic readers were shown to be recurrently mutated in a 
large variety of different tumor entities [108].         
In addition, the deposition of histone variants adds another layer of complexity to the histone 
code. Structural differences of histone variants are capable to change the biophysical 
properties of the core octamer. With the exception of histone H4, there are histone variants 
for all core histone proteins [109]. The amino-terminal tail of histone H3 (amino acid 1 to 40) 
is the most heavily modified tail of all four core histones with 21 potential  
modification sites [110]. 
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1.4.2 The Human Histone H3 Repertoire  
Histones are among the most highly conserved proteins throughout evolution. Phylogenetic 
trees for all four core histones show that histone H3 has diverged much slower than other 
histone proteins like H2A, H2B or the linker histone H1 [111]. The human non-centromeric 
H3 histone repertoire comprises three different groups of H3 proteins, which are classified 
according to their expression pattern. The expression of the first group of H3 proteins is 
directly linked to DNA replication during S-phase of the cell cycle, when large amounts of 
newly synthesized histones are needed to wrap up the duplicated DNA. Thus, this group is 
termed the replication-dependent or canonical group of H3 proteins. The expression of the 
second group of H3 proteins, named replication-independent or non-canonical H3 proteins, is 
generally not upregulated during DNA replication, although incorporation can also take place 
at this time point [112]. These replication-independent H3 proteins, as well as the third group 
of H3 histones, which are termed after their tissue specific expression patterns, are used to 
replace the canonical H3 in non-dividing cells to actively modulate chromatin structure and 
gene expression.         
Within the human genome, canonical histone H3 genes are found in two separate gene 
clusters on chromosome 6p22.1 (HIST1) and 1q21.2 (HIST2). While the gene cluster HIST1 
on chromosome 6 is composed of 10 genes (HIST1H3A-HIST1H3J), producing canonical H3 
termed H3.1, HIST2 on chromosome 1 produces canonical H3.2 from 3 gene copies 
(HIST2H3A, HIST2H3C, HIST2H3D). H3.2 differs in only one amino acid (serine at position 
96 instead of a cysteine) from the H3.1 protein. Like all canonical histone genes, HIST1 and 
HIST2 produce intronless mRNAs without poly-A tails, which are processed by a unique 
pathway including the recognition of a stem-loop structure within the 3’ UTR of canonical H3 
mRNAs, which allows massive production of these proteins at the beginning of S-phase 
[113]. Deposition of replication-dependent H3 is mediated by the chromatin assembly  
factor 1 subunit A (CAF1), which is directly tethered to the DNA replication fork by the DNA 
polymerase clamp PCNA (proliferating cell nuclear antigen) [114, 115].  
The second source of human H3 proteins, also known as the non-canonical H3 or H3.3, is 
encoded by two single copy genes H3F3A on 1q42.12 and H3F3B on 17q25.1. Both genes 
are transcribed into substantially different mRNAs, but translation produces an exactly 
identical H3.3 protein. While canonical H3 is encoded by multicopy, intronless genes, 
producing mRNA without a polyadenyl tail, H3F3A as well as H3F3B are transcribed into a 
polyadenylated mRNA from single copy genes containing several exons. The H3.3 protein 
differs in only 4 to 5 amino acids from canonical H3.2 and 3.1, respectively. Comparing solely 
the amino-terminal tail, there is only one single amino acid at position 31, which discriminates 
between replication-dependent H3 (alanine) and the replacement histone H3.3 (serine). This 
serine at position 31 of H3.3 represents an extra phosphorylation site besides the known 
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serine residues at position 10 and 28, which is not present in all other non-centromeric H3 
variants. Phosphorylated serine 31 of H3.3 has been found in metaphase cell nuclei at 
specific regions of the chromosomes bordering the centromeres [116]. In addition, the H3.3 
specific PTM H3.3S31p was detectable during mitosis and female meiosis in the urochordate 
Oikopleura dioica, indicating the evolutionary conservation of this epigenetic mark [117]. 
Phylogenetic analysis of all H3 variants suggests that a histone protein, similar to the 
mammalian histone H3.3, is the ancestor of all H3 variants in animals [118]. The uniquely 
present single H3 protein in some algae such as Nuclearia simpex differs from mammalian 
H3.3 in only one amino acid (serine 87 instead of alanine in mammals). A protein absolutely 
identical to human H3.3 is the unique H3 protein in unicellular eukaryotes like yeast [118]. 
Here, the histone protein has to undergo replication-independent as well as replication-
coupled assembly to chromatin. Although sharing more than 95% amino acid similarity, the 
subtle differences between H3.3 and canonical H3.1/H3.2 are sufficient to ensure that factors 
like the H3.3-specific chaperone DAXX discriminate between H3 and H3.3, thereby leading 
to fundamental differences in H3 and H3.3 localization. Recently, it has been shown that two 
amino acids within the histone fold domain at position 87 (alanine) and 90 (glycine) are 
responsible for the H3.3-specificity of its chaperone DAXX [119]. 
While canonical H3 is incorporated in a genome-wide manner during formation of new 
nucleosomes in S-phase via its chaperone CAF1, H3.3 incorporation is mediated by two 
distinct deposition pathways, depending on the H3.3 incorporation site [120, 121]. Deposition 
of H3.3 protein to gene bodies of actively transcribed genes is mediated by a mechanism 
including the histone chaperone HIRA (HIR histone cell cycle regulation defective  
homolog A) [120, 122, 123]. Furthermore, the chromodomain helicase DNA-binding protein 1 
(CHD1) contributes to the HIRA mediated deposition of H3.3 in fruit flies [124]. Reflecting its 
euchromatic deposition, the amino-terminal tail of H3.3 contains more activating/euchromatic 
PTMs (e.g. acetylation of lysine 4) than canonical H3.1 and H3.2 [125].  
Independently, the second H3.3 incorporation pathway uses the chaperones ATRX and 
DAXX to load H3.3 into pericentric and telomeric heterochromatin [121, 126]. The genes 
coding for these two proteins are frequently mutated in pedGBMs harboring H3F3A 
mutations, emphasizing the importance of the H3.3 chromatin remodeling pathway in 
pedGBM development. Further evidence for a specific H3.3 function is provided by H3.3 
knockout experiments, demonstrating that H3.3 deletions are not always lethal but do result 
in infertility in the fruit fly Drosophila melanogaster and the ciliate Tetrahymena thermophile 
[127-129]. This clearly indicates the importance of H3.3 in germline-specific chromatin 
remodeling. 
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In addition to canonical H3 and non-canonical H3.3, several H3 protein variants, which show 
tissue specific expression patterns, have been recently identified in humans. A gene on 1q42 
outside the known histone gene cluster codes for the H3 histone variant H3.4, which is also 
termed H3.T due to its testis-specific expression in human primary spermatocytes [130]. 
H3.4 differs in only 4 to 5 amino acids from H3.1/H3.2 and presumably uses a unique 
chromatin incorporation pathway [131]. A second testis-specific H3 variant is H3.5, which is 
encoded by H3F3C, a retrotransposed copy of H3F3B on chromosome 12p11.21 [132]. 
Compared to its ancestor H3.3, the H3.5 protein shows 5 amino acid differences including 
deletion of one of the two lysines at position 36 or 37. Furthermore, two additional H3 
variants at chromosome 5, termed H3.X and H3.Y have been identified in recent times, 
which are expressed in malignant and normal tissues including parts the human brain like the 
hippocampus, cerebellum or cerebral cortex  [133]. H3.X/H3.Y protein fundamentally differs 
from H3.3 in at least 25 amino acids. The amino acid alignment of all non-centromeric 
histone H3 variants is given in Figure 4, illustrating their high sequence homology.  
 
 
 
Figure 4. Protein Sequence Alignment of Human Non-Centromeric Histone H3 Variants. 
Chromosomal localization and gene symbols of human H3 variant coding genes are given for histone 
proteins H3.3 (ENSP00000355780), H3.1 (ENSP00000350275), H3.4 (ENSP00000355657), H3.5 
(ENSP00000339835) and H3.X/H3.Y [133]. Canonical H3.2 is not listed but differs from canonical 
histone H3.1 by only one amino acid (position 96: serine (S) instead of cysteine (C)). Amino acid 
residues differing from histone H3.3 are highlighted in grey. Protein similarity is also illustrated by the 
distance tree including the number of diverging amino acids from H3.3. Amino acids K27 and G34 that 
are mutated in pedGBM are highlighted in red.  
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To complete the human H3 repertoire, there is the centromeric H3 variant CENP-A 
(centromere protein A), which in many aspects differs from all non-centromeric H3 variants 
listed above [134]. CENP-A incorporation is unique to nucleosomes at the centromeres, 
which are required for proper chromosome segregation during cell division [135]. Sharing 
only about 50% amino acid identity with any other H3 histone, CENP-A harbors several 
structural differences, which define its exclusive deposition at centromeric nucleosomes.  
 
1.4.3 Histone Modifications in Cancer  
Genome integrity is of pivotal importance for survival of every single organism. Throughout 
lifetime, every cell is encountered by endogenous events or exogenous environmental 
agents, which interfere with genome stability. Efficient DNA repair as well as proper 
chromosome replication are key processes to ensure intactness of the genome. Chromatin 
structure, which is tightly regulated by a diverse set of mechanisms including covalent 
histone modifications and incorporation of histone variants, has been shown to essentially 
contribute to genome stability.  
Over the last decades it became obvious that cancer is a disease of the genome. If genomic 
stability is not ensured, alterations in the genome is one of the major driving forces of tumor 
development. Based on this knowledge, international efforts like the one conducted by the 
International Cancer Genome Consortium (ICGC) were initiated to find recurrent genetic 
alterations in different cancer types by using next generation sequencing technologies [12]. 
In doing so, mutations within the H3F3A gene, coding for the replication independent histone 
variant H3.3, were identified in pedGBMs, which formed the basis for the project presented in 
this thesis [30]. Never before, recurrent mutations within one of the highly conserved histone 
genes have been identified in cancer. However, the list of deregulated histone modifications 
in cancer is long and constantly growing.  
Several studies reported on global changes in histone methylation in various cancers types 
[70, 136]. In most of these entities, downregulated arginine and lysine methylation is 
associated with a higher risk of tumor recurrence and unfavorable outcome. One possible 
explanation for deregulated histone modifications in different neoplasms is the growing 
number of mutations within chromatin modifying genes including epigenetic writers, readers, 
and erasers. Epigenetic writers like the methyltransferases EZH2 or MLL1 are reported to be 
frequently altered in different tumor entities [137-139]. Looking at brain tumors, the 
epigenetic writers MLL2 and MLL3 are mutated in about 16% of medulloblastomas [11]. 
Furthermore, the translation of the epigenetic code in cancerous cells is frequently interfered 
by mutations of catalytically active and non-catalytic epigenetic readers [108]. Genetic 
alterations of epigenetic regulators with reader domains have been found within the 
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SMARCB1 or SMARCA4 gene in atypical teratoid/rhabdoid tumors (AT/RTs) and SMARCA4 
in medulloblastoma [11, 140, 141]. Lastly, impaired removal of histone modifications due to 
mutations of epigenetic erasers has also been identified in numerous human cancers 
including UTX/KDM6A (lysine (K)-specific demethylase 6A) mutations in approximately 12% 
of group 4 medulloblastomas [11].  
Besides point mutations in chromatin remodeling genes, complex genomic rearrangements 
have also been reported to contribute to deregulated histone modifications in cancer. In 
acute myeloid leukemia (AML), a recurrent translocation of chromosomes fuses the gene of 
the histone methyltransferase NSD1 to the NUP98 gene, leading to HOXA gene activation 
due to aberrant H3K36 trimethylation [142]. With regard to the different genetic events 
leading to deregulation of histone modifiers, it is obvious that specific chromosomal 
translocations are much more common in hematopoietic malignancies compared to solid 
tumors. However, deregulation of histone modifiers in solid tumors seem to be much more 
often caused by point mutations, deletions or amplifications [143].  
On top of alterations directly targeting the establishing, interpreting or erasing machineries of 
the histone code, mutations in other genes like IDH1 or IDH2 are described to interfere with 
histone modifications in cancer. Alterations of the IDH1 gene have been detected in about 
12% of glioblastoma, leading to high intracellular levels of the onco-metabolite  
2-hydroxyglutatrate, a potent inhibitor of histone demethylases [50, 144]. 
On the basis of these genetic events, it becomes apparent that genetic hits and the resulting 
epigenetic alterations actively contribute to cancer initiation and progression. This especially 
applies to tumors developing in the human brain, as a multitude of histone modifiers play a 
central role in nervous system development. This is underscored by various cognitive 
disorders that are caused by alterations in chromatin remodeling genes (reviewed in [145]). 
Diverse genetic events resulting in haploinsufficiency of the methyltransferase NSD1 are 
reported to result in Sotos syndrome, a genetic disorder associated with intellectual 
impairment [146]. While NSD1 is inactivated due to promoter hypermethylation in 
neuroblastomas and gliomas, this mechanism of NSD1 inactivation has never been 
described in entities outside of the nervous system like leukemias, lymphomas, breast or 
colon cancer [147]. Other examples of genetic alterations found to result in intellectual 
disability syndromes affect the methyl-CpG binding protein MECP2 in Rett syndrome, the 
histone demethylase JARID1C in X-linked mental retardation syndrome or the histone 
chaperone ATRX in alpha thalassemia/mental retardation syndrome [148-150].  
In conclusion, histone modifications play a fundamental role in human brain development. As 
a consequence, genetic alterations causing deregulated histone modification in the brain 
result in abnormal developmental defects or in tumorigenesis. The identification of histone 
 20 INTRODUCTION 
H3.3 mutations in pedGBMs represents a completely new field of research. It identifies 
mutations of histone proteins themselves as the cause of changes in the epigenetic code.  
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2 AIMS AND PROCEDURES 
Recent studies have shown that almost 50% of glioblastoma diagnosed in children harbor 
mutations in the H3.3/ATRX/DAXX chromatin remodeling pathway [30]. Noteworthy, 
recurrent mutations within the gene encoding the histone variant H3.3 (H3F3A) always led to 
amino acid substitutions at lysine 27 (K27M) or glycine 34 (G34R or G34V in rare cases) in 
the tail of H3.3. Furthermore, it has been shown that H3.3 mutated glioblastomas are 
characterized by mutation specific gene expression and DNA methylation profiles [48]. 
Following-up on these exciting findings, the thesis presented here aimed at the functional 
characterization of both H3.3 mutations (K27M or G34R) originally found in pediatric high 
grade gliomas.  
In order to do so, several cell lines including the pediatric glioblastoma cell line SF188 were 
genetically modified to stably overexpress mutant H3.3. These cell lines provided the basis 
for a main aspect of this project, focusing on the genetic and epigenetic differences between 
wildtype and mutant H3.3 overexpressing cells. While incorporation of mutant H3.3 protein 
into chromatin was analyzed by immunofluorescence and chromatin immunoprecipitation 
followed by next generation sequencing, alterations in posttranslational modifications of 
mutant H3.3 were investigated by immunohistochemistry, Western blot analysis and mass 
spectrometry. In addition, mutant H3.3 overexpressing cells were studied by genome-wide 
gene expression and DNA methylation profiling as well as functional readouts, assessing 
differences in cell proliferation and cell cycle progression.  
The second part of the work presented here was pointing at the tumorigenic potential of H3.3 
mutations. To determine whether mutant H3.3 is able to induce glioblastoma in vivo, 
retroviral gene transfer using the RCAS/Ntv-a system was used to overexpress H3.3 mutants 
in nestin-positive neural precursor cells in neonatal mice. Furthermore, this part of the project 
was conducted to establish new mutant H3.3 driven cell culture systems which would provide 
an excellent basis for subsequent preclinical studies.  
Complementing these functional analyses, this work was also thought to include molecular 
data generated on primary glioblastoma samples, which directly reflect the genetic and 
epigenetic situation in the patients suffering from these highly aggressive brain tumors.    
Taken together, this thesis aimed at the elucidation of the role and molecular mechanisms 
underlying glioblastoma initiation and progression, which in nearly half of the tumors seems 
to be tightly linked to H3.3 mutations.  
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3 MATERIALS & METHODS 
3.1 Materials 
3.1.1 Antibodies 
Antibody Source Dilution Company 
AU1-Tag Rabbit 1:1000 Abcam, Cambridge, UK 
GFP-Tag Mouse 1:1000 Roche Diagnostics, Mannheim, Germany 
H3.3 Rabbit 1:1000 Millipore, Billerica, USA 
H3.3S31p Rabbit 1:1000 Abcam, Cambridge, UK 
H3K27ac Mouse 1:1500 Diagenode, Liège, Belgium 
H3K27me1 Mouse 1:2000 Abcam, Cambridge, UK 
H3K27me3 Rabbit 1:3000 Abcam, Cambridge, UK 
H3K27me3 Mouse 1:5000 Abcam, Cambridge, UK 
H3K36me3 Rabbit 1:2000 Abcam, Cambridge, UK 
H3K4me3 Rabbit 1:1000 Diagenode, Liège, Belgium 
H3K9me3 Rabbit 1:1000 Diagenode, Liège, Belgium 
H4 Rabbit 1:5000 Abcam, Cambridge, UK 
HA-Tag (ChIP grade) Rabbit 1:5000 Abcam, Cambridge, UK 
Mouse (HRP) Goat 1:5000 Santa Cruz Biotechnology,  Santa Cruz, USA 
Rabbit (HRP) Goat 1:2500 Cell Signaling, Danvers, USA 
 
3.1.2 Primers & shRNAs 
Primer Sequence (5’-3’) 
dnTP53-AU1-ClaI-rev AATCGATTCAAATATAACGATAAGTATC 
dnTP53-AU1-rev ATCAAATATAACGATAAGTATCGTCTGAGTCAGGCCCCAC 
dnTP53-NotI-for TAGCGGCCGCGCCATGGAGGAGTCACAG 
H3.3-for GGATCCTCTCTGTACCATGGCTCGTAC 
H3.3-G34R-SDM-Dm-for CGGCGCCATCCACCGGCAGGGTGAAGAAGCC 
H3.3-G34R-SDM-Dm-rev GGCTTCTTCACCCTGCCGGTGGATGGCGCCG 
H3.3-G34R-SDM-Hs-for GTGCGCCCTCTACTGGAAGGGTGAAGAAACC 
H3.3-G34R-SDM-Hs-rev GGTTTCTTCACCCTTCCAGTAGAGGGCGCAC 
H3.3-HA-ClaI-rev GGAATCGATTCAAGCGTAGTCTGGGACGTC 
H3.3-HA-rev GCGGCCGCTCAAGCGTAGTCTGGGACGTCGTATGGGTATCCAGCACGTTCTCCACGTATGC 
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H3.3-K27M-SDM-Dm-for AGGCGGCCCGTATGTCGGCGCCATC 
H3.3-K27M-SDM-Dm-rev GATGGCGCCGACATACGGGCCGCCT 
H3.3-K27M-SDM-Hs-for AAGCCGCTCGCATGAGTGCGCCCTC 
H3.3-K27M-SDM-Hs-rev GAGGGCGCACTCATGCGAGCGGCTT 
H3.3-MutAnalysis for GTGATCGTGGCAGGAAAAGT 
H3.3-MutAnalysis rev CAAGAGAGACTTTGTCCCATTTT 
H3.3-NotI-for GAAGCGGCCGCTCTGTACCATGGCTCGTAC 
H3.3-TS-for TGGCTCGTACAAAGCAGACT 
H3.3-TS-rev GAAGGGAAGTTTGCGAATCA 
H3F3A for CAAACTTCCCTTCCAGCGTC 
H3F3A/B for CAGAGCGCAGCCATCGGTGC 
H3F3A/B rev TGGATGGCACACAGGTTGGT 
H3F3B for GAAGCTGCCCTTCCAGAGGT 
H3F3B rev CTCACTTGCCTCCTGCAAA 
H3F3B rev TTCGCTAGCCTCCTGCAGC 
SDHA for GACCATCTACGGAGCAGAGG 
SDHA rev TAGGACAGGGTGTGCTTCCT 
shH3F3A_1 CCGGGCGGAGACGTAAAGCATTAATCTCGAGATTAATGCTTTACGTCTCCGCTTTTTTG 
shH3F3A_2 CCGGCCACTATGATGGGAAACATTTCTCGAGAAATGTTTCCCATCATAGTGGTTTTTTG 
shH3F3A_3 CCGGGATGGCAACTAAATGGTGTTTCTCGAGAAACACCATTTAGTTGCCATCTTTTTTG 
shH3F3B_1 CCGGGCGCATTTATACCTTGCATAACTCGAGTTATGCAAGGTATAAATGCGCTTTTTG 
shH3F3B_2 CCGGGACTTGTTGGGTAGCTATTAACTCGAGTTAATAGCTACCCAACAAGTCTTTTTG 
 
3.1.3 Instruments 
Instrument Company 
ABI PRISM 3100 Genetic Analyzer Life Technologies, Darmstadt, Germany 
ABI PRISM 7700 PCR System Life Technologies, Darmstadt, Germany 
Agilent 2100 Bioanalyzer Agilent, Santa Clara, USA 
Bioruptor Sonication Device Diagenode, Denville, USA 
Eppendorf PCR Cycler (Mastercycler Gradient) Eppendorf, Hamburg, Germany 
L8-M Ultracentrifuge Beckmann Coulter, Krefeld, Germany 
Leica DM IRB/E inverted microscope Leica, Wetzlar, Germany 
Micro-Dismembrator Braun Biotech, Melsungen, Germany 
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Mini Protean Gel Transfer System BioRad, Munich, Germany 
Mithras LB 940 Microplate Reader Berthold Technologies, Bad Wildbad, Germany 
NanoDrop ND-1000 spectrophotometer NanoDrop, Wilmington, USA 
Qubit 2.0 Fluorometer Life Technologies, Darmstadt, Germany 
TCS SP5 confocal laser scanning microscope Leica, Wetzlar, Germany 
ViCell XR cell counter Beckmann Coulter, Krefeld, Germany 
 
3.1.4 Biochemicals and Reagents 
Reagent Supplier 
Absolute SYBR Green ROX Mix ABgene, Epsom, UK 
Acetone Sigma-Aldrich, Munich, Germany 
Ampicillin Roche Diagnostics, Mannheim, Germany 
Bovine serum albumin Sigma-Aldrich, Munich, Germany 
Cell culture dish (10 cm, 14.5 cm) TPP Techno Plastic Products, Trasadingen, Switzerland 
Cell culture plates (6 well, 12 well) Nunc, Wiesbaden, Germany 
Chicken egg albumin Sigma-Aldrich, Munich, Germany 
Coverslips (circular) Ted Pella, Redding, USA 
Dithiothreitol (DTT) Sigma Aldrich, Munich, Germany 
DMEM media (for DF1 cells) ATCC, Wesel, Germany 
DMEM medium (4.5 g/L glucose) Life Technologies, Darmstadt, Germany 
dNTP Mix (100 µM each) Fermentas, St.LeonRot, Germany 
ECL (plus) WB Detection Reagents GE Healthcare, München, Germany 
Ethanol (100%) Merck, Darmstadt, Germany 
Fetal calf serum (FCS) Biochrom AG, Berlin, Germany 
Fetal calf serum (FCS) (for DF1 cells) ATCC, Wesel, Germany 
Formaldehyde Merck, Darmstadt, Germany 
Formamide Merck, Darmstadt, Germany 
FuGENE HD transfection reagent Roche Diagnostics, Mannheim, Germany 
Gelatin from cold water fish skin (45%) Sigma-Aldrich, Munich, Germany 
H2O Braun Biotech, Melsungen, Germany 
Horseradish peroxidase (HRP) 
conjugated streptavidin Dako, Carpinteria, USA 
Hydrogen peroxide Dako, Carpinteria, USA 
L-glutamin Life Technologies, Darmstadt, Germany 
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Methanol Merck, Darmstadt, Germany 
Milk powder Roth, Karlsruhe, Germany 
Needle (0.9 mm) Braun Biotech, Melsungen, Germany 
NuPAGE Antioxidant Life Technologies, Darmstadt, Germany 
NuPAGE Bis-Tris Precast Gels 
(12 or 10 well; 1 mm)  Life Technologies, Darmstadt, Germany 
NuPAGE SDS Running Buffer (20x) Life Technologies, Darmstadt, Germany 
NuPAGE SDS Sample Buffer (4x) Life Technologies, Darmstadt, Germany 
Oligo(dT) primer Thermo Fisher Scientific, Waltham USA 
OptiMEM medium Life Technologies, Darmstadt, Germany 
Penicillin/Streptomycin (1000 U/ml) Life Technologies, Darmstadt, Germany 
Perchloric acid Sigma-Aldrich, Munich, Germany 
Phosphate buffered saline (PBS) Life Technologies, Darmstadt, Germany 
pLVX-Puro plasmid Clontech, Mountain View, USA 
pMD2.G plasmid Addgene, Cambridge, USA 
Polybrene Millipore, Billerica, USA 
Polyvinylidene fluoride (PVDF) membrane Sigma-Aldrich, Munich, Germany 
Porpidium iodide Sigma-Aldrich, Munich, Germany 
Protein A/G sepharose beads GE Healthcare, München, Germany 
ProtoBlue Safe National Diagnostics, Atlanta, USA 
psPAX2 plasmid Addgene, Cambridge, USA 
Random hexamer primers Life Technologies, Darmstadt, Germany 
Reaction tubes (1.5 ml/2 ml) Eppendorf, Hamburg, Germany 
Sodium Acetate Roth, Karlsruhe, Germany 
Spectra multicolor broad range protein ladder Fermentas, St.LeonRot, Germany 
Syringe filters (0.45 µm) Millipore, Billerica, USA 
TransIT transfection reagent Mirus Bio, Madison, USA 
Triton-X 100 AppliChem, Darmstadt, Germany 
Trypsin-EDTA (1x) Sigma-Aldrich, Munich, Germany 
Universal Human Reference RNA Agilent, Santa Clara, USA 
Vectashield HardSet Mounting Medium with 
DAPI Vector Laboratories, Burlingame USA 
X-ray films, Super RX FUJIFilm, Tokyo, Japan 
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3.1.5 Cells & Cell Lines 
Cell Type Company 
DF1 chicken fibroblasts ATCC, Wesel, Germany 
HEK293T Cells ATCC, Wesel, Germany 
OneShot TOP10 competent E. coli cells Life Technologies, Darmstadt, Germany 
SF188 Glioblastoma Cells UCSF, San Francisco, USA 
 
3.1.6 Kits 
Enzyme Company 
ClaI New England Biolabs (NEB), Ipswich, USA 
DNase  Life Technologies, Darmstadt, Germany 
GoTaq DNA polymerase  Promega, Mannheim, Germany 
NotI New England Biolabs (NEB), Ipswich, USA 
SuperScript II reverse transcriptase Life Technologies, Darmstadt, Germany 
T4 DNA ligase Roche Diagnostics, Mannheim, Germany 
XbaI Fermentas, St. Leon Rot, Germany 
XhoI Fermentas, St. Leon Rot, Germany 
 
3.1.7 Enzymes 
Kit Company 
BigDye Terminator v3.1 Cycle 
Sequencing Kit 
Life Technologies, Darmstadt, Germany 
CellTiter 96 AQueous Non-Radioactive 
Cell Proliferation Assay 
Promega, Mannheim, Germany 
CloneJet PCR cloning kit Thermo Fisher Scientific, Waltham USA 
DNA 1000 Kit Agilent, Santa Clara, USA 
High Sensitivity DNA Kit Agilent, Santa Clara, USA 
Histone Purification Mini Kit Active Motif, La Hulpe, Belgium 
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MinElute PCR Purification Kit Qiagen, Hilden, Germany 
pcDNA3.1/V5-His TOPO TA Expression 
Kit 
Life Technologies, Darmstadt, Germany 
PCR purification kit Norgen, Thorold, Canada 
pGEM-T Easy Vector System Cloning Kit Promega, Mannheim, Germany 
QIAamp DNA Mini Kit Qiagen, Hilden, Germany 
QIAprep Spin Mini/MaxiPrep Kit Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
Qubit dsDNA HS Assay Kit Life Technologies, Darmstadt, Germany 
QuikChange II Site-Directed Mutagenesis 
Kit 
Agilent, Santa Clara, USA 
RNA 6000 Nano Kit Agilent, Santa Clara, USA 
RNeasy Mini Kit Qiagen, Hilden, Germany 
 
3.1.8 Buffers and solutions 
Buffer Ingredients 
ChIP Buffer A 100 mM Tris-HCl pH 9.4, 10 mM DTT 
ChIP Buffer B 
10 mM HEPES pH 6.5, 10 mM EDTA,  
0.5 mM EGTA, 0.25% Triton X-100 
ChIP Buffer C 
100 mM HEPES pH 6.5, 10 mM EDTA,  
0.5 mM EGTA, 200 mM NaCl 
ChIP Buffer D 
50 mM Tris-HCl pH 8.0, 10 mM EDTA,  
1% SDS, protease inhibitors 
ChIP Dilution Buffer 
20 mM Tris-HCl pH 8.0, 1% Triton X-100,  
2 mM EDTA, 150 mM NaCl, protease inhibitors 
ChIP Elution Buffer 100 mM NaHCO3, 1% SDS 
ChIP High salt buffer 
20 mM Tris-HCl pH 8.0, 1% Triton X-100,  
2 mM EDTA, 500 mM NaCl 
ChIP LiCl Buffer 
100 mM Tris-HCl pH 8.0, 400 mM LiCl, 1% NP-
40, 1% Na-deoxycholate, 1mM EDTA 
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Citrate buffer (pH 6.0) 10 mM sodium-citrate, 0.05% Tween-20  
TBST 
150 mM NaCl, 10 mM Tris, 0.1% Tween-20, pH 
7.4 
TE Buffer (pH 8.0) 10 mM Tris pH 8.0, 1 mM EDTA 
Western Blot Transfer Buffer 
25 mM Tris pH 8.8, 200 mM glycine, 20% 
methanol 
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3.2 Methods 
3.2.1 Extraction of genomic DNA (gDNA) 
For isolation of high quality gDNA out of tumor tissue, frozen tissue was pulverized before 
lysis using a Micro-Dismembrator (Braun Biotech). Afterwards, gDNA was extracted as 
previously described [151]. Genomic DNA out of cell pellets was conducted by using the 
QIAamp DNA Mini Kit (Qiagen) following the manufacturer’s protocol. After extraction, DNA 
concentration was measured by using a NanoDrop ND-1000 Spectrophotometer 
(NanoDrop). If necessary, DNA quality was assessed by running a DNA 1000 Kit (Agilent) on 
an Agilent 2100 Bioanalyzer (Agilent) as described in the manufacturer’s protocol.  
3.2.2 Extraction of RNA 
Isolation and purification of RNA from cell pellets (minimum 1x105 cells) was performed by 
using the RNeasy Mini Kit (Qiagen). For isolation of RNA out of primary tissue, at least  
30 mg of frozen tissue was pulverized before lysis by using a Micro-Dismembrator (Braun 
Biotech). Subsequently, starting material was lysed by adding 350 µl RLT buffer and passing 
the lysate through a 0.9 mm needle (Braun). Afterwards, cell lysates were applied to RNeasy 
spin columns (Qiagen) and RNA isolation was carried out according to the manufacturer’s 
protocol. Total RNA was eluted in a final volume of 30 µl H2O (Braun Biotech). RNA 
concentration was measured by using a NanoDrop ND-1000 Spectrophotometer 
(NanoDrop). If necessary, RNA quality was assessed by running a RNA 6000 Nano Chip 
(Agilent) on an Agilent 2100 Bioanalyzer (Agilent) as described in the manufacturer’s 
protocol.  
3.2.3 Preparation of Plasmid DNA 
Plasmid DNA from transformed OneShot TOP10 competent E. coli cells (Life Technologies) 
was isolated using either the QIAprep Spin MiniPrep or MaxiPrep Kit (Qiagen). Therefore, 
transformed bacteria were grown in LB-media containing 100 µg/ml ampicillin (Roche) at 
37°C for at least 8 hours with constant shaking. Af ter centrifugation at 4000 rpm at 4°C for 15 
minutes, pelleted bacteria were resuspended in buffer P1 and lysed by adding the respective 
amount of buffer P2. By adding neutralization buffer P3 and centrifugation at 13300 rpm at 
4°C for 10 minutes, genomic DNA and proteins were r emoved and circular plasmid DNA was 
purified using QIAprep spin column with silica-membranes and several washing steps 
according to the manufacturer’s protocol. Finally, purified plasmid DNA was eluted in 50 µl 
(MiniPrep) or 300 µl (MaxiPrep) H2O (Braun Biotec). Plasmid DNA concentration was 
measured by using a NanoDrop ND-1000 Spectrophotometer (NanoDrop). 
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3.2.4 Reverse Transcription (cDNA Synthesis) 
Synthesis of cDNA from purified RNA was carried out using SuperScript II reverse 
transcriptase (Life Technologies). Before reverse transcription, 1 µg total RNA was digested 
with 1 µl DNase (1 U/µl) (Life Technologies) and 2 µl first strand buffer (5x) in a total volume 
of 10 µl at 20°C for 20 minutes. After adding 1 µl EDTA (25 mM), cDNA priming was 
performed by using Oligo(dT) primers (Thermo Scientific) as well as random hexamer 
primers (3 µg/µl) (Life Technologies). Primer annealing was carried out by heating the 
reaction to 42°C for 10 minutes followed by 65°C fo r additional 10 minutes. After the addition 
of 1 µl DTT (0.1 M) (Sigma), 2 µl first strand buffer (5x), 1 µl dNTP Mix (10 µM each) 
(Fermentas) and  
1 µl H20 (Braun), the reaction was incubated at 42°C for 2 minutes. Reverse transcription 
was initiated by adding 1 µl SuperScript II and incubation at 42°C for 50 minutes. The 
enzymatic reaction was stopped by incubation at 70°C for 15 minutes. Finally, 20 µl of cDNA 
were diluted with H2O (Braun) to a total volume of 60 µl.  
3.2.5 Sanger Sequencing 
Sequencing of purified PCR products or plasmid DNA was performed by using the BigDye 
Terminator v3.1 Cycle Sequencing Kit (Life Technologies). In short, 20 ng of PCR product or 
500 ng of plasmid DNA was mixed with 1 µl BigDye solution, 2 µl BigDye sequencing buffer 
(5x) and 1 µl sequencing primer (10 µM) in a total volume of 10 µl on ice. Sequencing PCR 
was done for 25 cycles (step 2-4) using an Eppendorf PCR Cycler (Eppendorf) as follows: 
Initial denaturation at 96°C for 3 minutes (1), den aturation at 96°C for 30 seconds (2), primer 
annealing at 51°C for 15 seconds (3), extension at 60°C for 4 minutes (4) and constant 
cooling at 4°C (5). Afterwards PCR products were pu rified by precipitation by adding and  
25 µl 100% ethanol (Merck) and 1 µl 3 M sodium acetate (Roth). After centrifugation at 
13300 rpm at 4°C for 30 minutes, precipitates were washed with 200 µl 60% ethanol (Merck) 
and centrifuged again at 13300 rpm at 4°C for 15 mi nutes. Finally, precipitates were air dried 
at room temperature, resuspended in 10 µl formamide (Merck) and sequenced using an ABI 
PRISM 3100 Genetic Analyzer (Life Technologies). 
3.2.6 Mutation Analysis of the Genomic H3F3A Locus  
To determine the H3F3A mutation status in pedGBM samples, the first exon of H3F3A was 
PCR amplified out of genomic DNA using GoTag DNA polymerase (Promega) and primers 
H3.3-MutAnalysis for/H3.3 MutAnalysis rev (annealing temperature 56°C; 30 seconds 
extension time at 72°C). After PCR purification usi ng the PCR purification Kit (Norgen), 
amplicons were sequenced by using the BigDye Terminator v3.1 Cycle Sequencing Kit (Life 
Technologies) and an ABI PRISM 3100 Genetic Analyzer (Life Technologies). 
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3.2.7 Mutation Analysis of H3F3A Transcripts  
Isolated RNA of pedGBM samples was reverse transcribed into cDNA using SuperScript II 
reverse transcriptase (Life Technologies). A region including the codons for both H3.3 
mutations was amplified out of this cDNA by PCR amplification using GoTag DNA 
polymerase (Promega) and primers H3.3-TS-for/H3.3-TS-rev (annealing temperature 60°C; 
30 seconds extension time at 72°C). After purificat ion using the PCR purification Kit 
(Norgen), PCR products were cloned into the pGEM-T Easy Vector System (Promega) 
according to manufacturer’s instructions. After transformation into OneShot TOP10 
competent E. coli cells (Life Technologies), single clones were grown on agar plates 
containing 100 µg/ml ampicillin (Roche). The next day, clones were picked to perform PCR 
amplification with GoTag DNA polymerase (Promega) and primers H3.3-TS-for/H3.3-TS-rev 
(annealing temperature 60°C; 30 seconds extension t ime at 72°C). PCR products were again 
purified and subjected to Sanger sequencing using primers H3.3-TS-for or H3.3-TS-rev. 
3.2.8 Polymerase Chain Reaction (PCR) 
PCR reaction using GoTaq DNA polymerase (Promega) was performed using 0.25 µl DNA 
polymerase (5 U/µl), 5 µl GoTag Reaction Buffer (5x), 1 µl dNTP Mix (10 µM each) 
(Fermentas), 1 µl forward primer (10 µM), 1 µl reverse primer (10 µM) and 20 ng of template 
(gDNA, cDNA, or plasmid DNA) in a total volume of 25 µl. If not denoted differently, PCR was 
performed for 40 cycles (steps 2-4) in an Eppendorf PCR Cycler (Eppendorf) with the 
following Cycler Conditions: Initial denaturation at 95°C for 2 minutes (1), denaturation at 
95°C for 30 seconds (2), primer annealing (3) and e xtension (4) as indicated, followed by 
final extension at 72°C for 5 minutes (5) and const ant cooling at 10°C (6). GoTaq DNA 
polymerase lacks proofreading activity and produces PCR products with 3’dA overhangs. 
3.2.9 Quantitative Realtime PCR (qRT-PCR) 
For mRNA expression analysis, high quality RNA was isolated and reverse transcribed into 
cDNA as described earlier. Each cDNA sample was analyzed in triplicates using the ABI 
PRISM 7700 PCR System (Applied Biosystems) and Absolute SYBR Green ROX Mix 
(ABgene). Gene expression was normalized to the endogenous housekeeping gene 
succinate dehydrogenase complex subunit A (SDHA) using primers SDHA for/rev. 
Amplification of genomic DNA was excluded by using intron-spanning primers if possible. 
Relative gene expression levels were calculated as described by Pfaffl et al. [152].  
3.2.10 Cloning of C-terminally HA-tagged H3.3 Overexpression Constructs 
The open reading frame (ORF) of histone H3.3 was amplified out of reverse-transcribed 
Universal Human Reference RNA (Agilent) using the GoTaq DNA polymerase (Promega) 
and primers H3.3-for/H3.3-HA-rev (annealing temperature 59°C; 45 seconds extension time 
at 72°C). After PCR amplification, 20% of the PCR r eaction was separated by agarose gel 
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electrophoresis (1.5%) to check for correct amplicon size. The remaining 80% of the PCR 
reaction was subjected to PCR clean up using the PCR purification kit (Norgen). Purified 
PCR product was cloned into the mammalian overexpression vector pcDNA3.1 (Life 
Technologies) followed by transformation into OneShot TOP10 competent E. coli cells (Life 
Technologies). Single clones were subjected to Sanger sequencing to confirm the integrity of 
the C-terminally HA-tagged H3.3-WT overexpression construct (pcDNA_H3.3-WT-HA).  
C-terminally HA-tagged K27M and G34R mutated overexpression constructs were generated 
by using H3.3-WT-HA, which was subjected to site-directed mutagenesis using primers 
H3.3-K27M-SDM-Hs-for/ H3.3-K27M-SDM-Hs-rev and H3.3-G34R-SDM-Hs-for/ H3.3-G34R-
SDM-Hs-rev and the QuikChange II Site-Directed Mutagenesis Kit (Agilent). Integrity of  
C-terminally HA-tagged K27M (pcDNA_H3.3-K27M-HA) and G34R (pcDNA_H3.3-G34R-HA) 
mutated overexpression constructs was verified by Sanger sequencing. 
3.2.11 EGFP/CFP-tagged H3.3 Overexpression Constructs 
The wildtype histone H3.3 overexpression construct (H3.3-WT-pEGPF-N1), which was  
C-terminally tagged with the enhanced green fluorescent protein (EGFP), was provided by 
Philippe Collas (Institute of Basic Medical Sciences, Oslo, Norway). C-terminally EGFP-
tagged K27M and G34R mutated overexpression constructs were generated by performing 
site-directed mutagenesis. Therefore, H3.3-WT-pEGPF-N1, was chosen as the template to 
conduct site-directed mutagenesis using primers H3.3-K27M-SDM-Dm-for/H3.3-K27M-SDM-
Dm-rev and H3.3-G34R-SDM-Dm-for/H3.3-G34R-SDM-Dm-rev. Mutagenesis was performed 
using the QuikChange II Site-Directed Mutagenesis Kit (Agilent). Finally, all constructs were 
analyzed by Sanger sequencing to confirm sequence integrity.  
The overexpression construct of wildtype H3.3 fused to the cyan fluorescent protein (CFP) 
was a generous donation of Karsten Rippe (Genome Organization & Function, German 
Cancer Research Center (DKFZ), Heidelberg, Germany). It consists of the H3.3 ORF cloned 
into the pEYFP-C1 backbone (Clontech), which was modified to express CFP instead of 
EYFP. 
3.2.12   Transfection 
Transfection of SF188 glioblastoma or HEK293T cells was performed by using TransIT 
transfection reagent (Mirus Bio). After seeding 1x106 cells in a 14.5 cm cell culture dish (TPP) 
in high glucose DMEM medium (Life Technologies) supplemented with 10% FCS (v/v) 
(Biochrom), 1% penicillin/streptomycin (v/v) (Life Technologies) and 1% 200 mM L-glutamin 
(v/v) (Life Technologies), cells were cultivated for 24 hours at 37°C and 5% CO 2. For 
transfection, 200 µl OptiMEM medium (Life Technologies) were mixed with 20 µg 
overexpression plasmid and 60 µl TransIT transfection reagent. For double transfections the 
amount of each plasmid was reduced to 10 µg. Formation of transfection complexes was 
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performed at room temperature for 20 minutes, before adding the mixture dropwise to the 
cells and cultivation for 24 hours at 37°C and 5% C O2. The next day, cells were washed with 
PBS (Life Technologies) and supplemented with new DMEM medium (Life Technologies). 
Expression of EGFP- and CFP-tagged H3.3 proteins was analyzed by fluorescence 
microscopy 72 hours after transfection.   
For imaging of fluorescently-labeled H3.3 proteins, SF188 glioblastoma cells were grown on 
circular glass coverslips (Ted Pella) in 12 well cell culture plates (Nunc) in DMEM medium 
(Life Technologies). The day before transfection, 5x104 cells were seeded in a 12 well and 
incubated for 24 hours at 37°C and 5% CO 2. Transfection was performed as described 
above using 3 µl TransIT transfection reagent (Mirus Bio) and 1 µg plasmid DNA. After 
medium exchange 24 hours post transfection, cells were fixed and permeabilized at least 
another 48 hours later. For fixation, cells were treated with 2% formaldehyde (Merck) in PBS 
(Life Technologies) at room temperature for 20 minutes. After three washing steps in PBS, 
cells were incubated with 0.1% Triton-X 100 (AppliChem) at room temperature for 30 
minutes. After additional three washing steps in PBS, coverslips were mounted in 
Vectashield HardSet Mounting Medium with DAPI (Vector) on glass slides followed by 
confocal imaging using a TCS SP5 confocal laser scanning microscope (Leica). 
3.2.13 Cloning of C-terminally HA-tagged H3.3 pLVX-Puro Constructs 
In order to overexpress H3.3 variants by lentiviral transduction, the ORF of H3.3 was cloned 
into the pLVX-Puro plasmid (Clontech). Therefore, H3.3-pJet1.2 constructs (pJet1.2_H3.3-
WT-HA, pJet1.2_H3.3-K27M-HA, pJet1.2_H3.3-G34R-HA), generated in 3.2.24 were double-
digested with XhoI and XbaI restriction enzymes (Fermentas). Digested constructs were 
separated by agarose gel electrophoresis (1%) and inserts were gel extracted using the 
QIAquick Gel Extraction Kit (Qiagen) according to manufacturer’s instructions. Subsequently, 
DNA concentration was quantified by using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop). T4 DNA ligase (1 U/µl) (Roche) was used to ligate the insert into linearized 
pLVX-Puro plasmid in a vector/insert ratio of 1:3. Ligation was performed overnight at 4°C 
before transformation into OneShot TOP10 competent E. coli cells (Life Technologies). 
Single clones, growing on agar plates containing 100 µg/ml ampicillin (Roche), were 
subjected to Sanger sequencing before using H3.3-pLVX constructs (pLVX_H3.3-WT-HA, 
pLVX_H3.3-K27M-HA, pLVX_H3.3-G34R-HA) for lentivirus production.  
3.2.14 Production of Lentiviral Particles  
To generate lentiviral particles, HEK293T cells (passage number < 10) were co-transfected 
with the following three constructs: The transgene containing pLVX-Puro vector (4 µg), the 
packaging vector psPAX2 (2 µg) (Addgene) and the envelope vector pMD2.G (2 µg)  
(Addgene). For each transfection, 4x106 cells were seeded in a 10 cm cell culture dish (TPP) 
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in high glucose DMEM medium (Life Technologies) supplemented with 30% fetal calf serum 
(FCS) (v/v) (Biochrom), 1% penicillin/streptomycin (v/v) (Life Technologies) and 1% 200 mM 
L-glutamin (v/v). Cells were cultivated till reaching 70% confluency at 37°C and 5% CO 2.  
Co-transfection was performed using the respective amount of plasmid (see above) and  
30 µl TransIT transfection reagent (Mirus Bio) in a total volume of 600 µl OptiMEM medium 
(Life Technologies). After formation of transfection complexes for 20 minutes at room 
temperature, the mixture was added dropwise to the HEK293T cells. Medium exchange 24 
hours later was followed by the first virus harvest another 24 hours later (48 hours after 
transfection) and a second virus harvest 72 hours after transfection. Transfection efficiency 
was simultaneously monitored by confirming GFP expression in HEK293T cells using 
fluorescence microscopy (Leica). Virus harvest was executed by removing the virus 
containing supernatant, filtering using a 0.45 µm syringe filter (Millipore) and 
ultracentrifugation using a SW41 rotor in a L8-M Ultracentrifuge (Beckmann) for 90 minutes 
at 4°C at 25,000 rpm. Subsequently, the supernatant  was removed and the virus pellet was 
dried at room temperature. Viral particles were resuspended in 100 µl OptiMEM medium (Life 
Technologies) and stored in 10 µl aliquots at -80°C .  
Virus titer and the multiplicity of infection (MOI) was determined by transduction of HEK293T 
cells or respective target cells with different amounts of GFP containing lentiviral particles of 
the same virus harvest, which were generated simultaneously. At least 48 hours after 
transduction, the number of GFP positive cells was determined by flow cytometry. Virus titer 
was calculated as follows:  
Titer [transduction units/µl] = (cell number at transduction time point) x (percentage of 
GFPpositive/100) x (dilution factor) x (1/volume). 
3.2.15 Lentiviral Transduction 
Transduction of SF188 glioblastoma or HEK293T cells was performed in 6 well cell culture 
plates (Nunc), seeding 1x105 cells the day before transduction. Lentiviral particles containing 
either one of the three H3.3 variants (H3.3-WT-HA, H3.3-K27M-HA, H3.3-G34R-HA) or a 
shRNA targeting the untranslated region (UTR) of endogenous H3F3A or H3F3B gene were 
added to the cells with an MOI of 5 in the presence of 8 µg/ml polybrene (Millipore). After 24 
hours the virus containing supernatant was removed, cells were washed with PBS (Life 
Technologies) and new DMEM medium (Life Technologies) was added. For overexpression 
experiments, viral particles containing empty pLVX-Puro vectors were used in parallel as a 
control. As a control for all H3.3 silencing experiments, viral particles harboring non-target 
shRNA were used simultaneously. Transduction efficiency was calculated by flow cytometry 
of GFP overexpressing cells, which were transduced in parallel.  
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3.2.16 Chromatin Immunoprecipitation (ChIP) 
Transduced SF188 glioblastoma cells were seeded in 14.5 cm cell culture dishes (2x each) 
(TPP) and incubated in DMEM medium (Life Technologies) at 37°C and 5% CO 2 until 
reaching 90% confluence. ChIP experiments were performed on SF188 cells transduced for 
4 weeks with H3.3 variants (pLVX_H3.3-WT-HA, pLVX_H3.3-K27M-HA, pLVX_H3.3-G34R-
HA, pLVX-EMPTY) with an MOI of 5. Cells were harvested by trypsination (Sigma) and 
centrifugation at 1000 rpm at 4°C for 10 minutes. P ellet was resuspended in 1 ml ChIP  
Buffer A and incubated at 4°C for 15 minutes follow ed by 30°C for 15 minutes. After 
centrifugation at 1000 rpm at 4°C for 5 minutes, th e pellet was resuspended in 1 ml ChIP 
Buffer B and incubated at 4°C for 5 minutes. Subseq uently, samples were centrifuged and 
pellets were incubated in 1 ml ChIP Buffer C at 4°C  for 5 minutes. Centrifugation was 
repeated before resuspending the pellet in 300 µl ChIP Buffer D and sonification at 4°C for 
60 cycles (power ON for 30 seconds followed by power OFF for 30 seconds) in a 1.5 ml 
reaction tube (Eppendorf) using a Bioruptor Sonication Device (Diagenode). In doing so, 
chromatin was adjusted to an average fragment size of 300 bp. Cell debris was removed by 
centrifugation at 13300 rpm at 4°C for 5 minutes an d chromatin containing supernatant was 
diluted by adding 2.5 ml ChIP-dilution buffer. An aliquot of 100 µl was removed and stored at 
-80°C (Input). Each ChIP experiment was split into 3 parts containing 900 µl chromatin each. 
Preclearing was performed at 4°C for 1 hour by usin g 20 µl of a mixture of protein A and 
protein G sepharose beads (1:1) (GE Healthcare), which were washed three times in ChIP 
dilution buffer and blocked with 5% bovine serum albumin (Sigma) in ChIP dilution buffer, 
gelatin (Sigma) and chicken egg albumin (Sigma) at 4°C for 2 hours and constant tumbling. 
After removal of sepharose beads and unspecifically bound DNA by centrifugation at  
2000 rpm at 4°C for 2 minutes, precleared chromatin  was added to 20 µl fresh sepharose 
beads, which were washed and blocked as described above. Immunoprecipitation was 
performed at 4°C overnight and constant tumbling by  adding 2 µl (2 µg) ChIP-grade anti-HA 
antibody (Abcam ab9110). The following day, beads, were washed as indicated by addition 
of the respective buffer (4°C), incubation at room temperature with constant tumbling for 10 
minutes and subsequent centrifugation at 2000 rpm at 4°C for 2 minutes (3x High salt buffer, 
3x LiCl Buffer, 1x TE buffer). Finally, bound DNA was eluted by adding 60 µl Elution buffer 
and constant shaking at 1200 rpm at room temperature for 15 minutes followed by 
centrifugation (10000 rpm at room temperature for 1 minute). The elution step was repeated 
once and both elutions were pooled (120 µl). Reverse crosslinking was performed by adding 
3.6 µl 5 M sodium acetate (Roth) and incubation at 65°C overnight. Input samples (100 µl) 
were thawed and reverse crosslinked at 65°C overnig ht by adding 2 µl 5 M sodium acetate. 
The next day, all three samples of one ChIP experiment were pooled by using a shared 
MinElute PCR purification Column (Qiagen) and a final H2O elution volume of 12 µl. Total 
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amount of precipitated DNA was calculated by using Qubit 2.0 Fluorometer (Life 
Technologies) and a dsDNA HS assay Kit (Life Technologies). In addition, fragment size was 
checked by running a High Sensitivity DNA Chip (Agilent) on an Agilent 2100 Bioanalyzer 
(Agilent).  
Library preparation and sequencing of bound DNA fragments was performed according to 
the manufacturer’s instructions at the DKFZ Genomics and Proteomics Core Facility 
(Heidelberg, Germany) by using an Illumina HiSeq 2000 sequencing system. 
For ChIP-Seq data analysis, sequencing reads were aligned to human genome build 
GRCh37 using a Burrows–Wheeler aligner (BWA). Post-processing of the aligned reads 
included merging of lane-level data and removal of duplicate read pairs using Picard tools 
(http://picard.sourceforge.net). Only uniquely aligned reads were considered for downstream 
analysis, and aligned reads were converted to the SAM/BAM format using SAMtools [153]. 
Reads within bins of 10 kB were counted using custom Python scripts and resulting data was 
interpreted using R. 
3.2.17 Cell Proliferation Assay (MTS Assay) 
Cell growth characteristics were assessed by performing MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay using the CellTiter 96 
AQueous Non-Radioactive Cell Proliferation Assay (Promega). Equal amounts of transduced 
cells were seeded in triplicates into 96-well plates and incubated in a 5% CO2 humidified 
incubator at 37°C for 24 hours. The next day, MTS s olution was added followed by 
incubation at 37°C for 1-3 hours. Finally, absorban ce at 490 nm was measured by using an 
Mithras LB 940 microplate reader (Berthold Technologies). As described, the absorbance at 
490 nm is proportional to the number of living cells in a 96-well [154].  
3.2.18 Cell Cycle Analysis (Nicoletti Assay) 
Quantitative information about cell proportions residing in different cell cycle phases was 
determined by performing Nicoletti assay, which uses the immunofluorescence detection of 
the DNA-intercalating substance propidium iodide (PI) to calculate the amount of DNA in the 
cell nucleus [155]. Transduced cells were seeded in equal amounts in 6-well plates (Nunc) 
and cultured in a 5% CO2 humidified incubator at 37°C for 24 hours. Afterwa rds, cells were 
incubated in hypotonic Nicoletti buffer containing 50 µg/ml PI (Sigma Aldrich), 0.1% sodium 
citrate and 0.1% Triton X-100 (Sigma Aldrich) protected from light at 4°C for 4 hours. Finally, 
DNA content of cell nuclei was analyzed by flow cytometry.  
3.2.19 Isolation of Histone Proteins 
The Histone Purification Mini Kit (Active Motif) was used to isolate and purify histone proteins 
from cell culture and tissue samples. For isolation of histones out of primary tissue, 
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approximately 100 mg of frozen tissue were pulverized by using a Micro-Dismembrator 
(Braun Biotech). Cell pellets (minimum 5x106 cells) or pulverized tissue was directly 
resuspended in an appropriate volume of ice cold extraction buffer and lysed on a rotating 
platform at 4°C for at least 1 hour. After removal of cell debris by centrifugation at  
13300 rpm at 4°C for 5 minute, the supernatant was neutralized by adding 1:4 volume of 
neutralization buffer (5x). In parallel, spin columns were equilibrated by the addition of 500 µl 
equilibration buffer and centrifugation at 800 rpm at 4°C for 3 minutes to load neutralized 
sample in 500 µl steps to the column with the same centrifugation conditions. Afterwards, 
columns were washed three times with 500 µl ice cold washing buffer and centrifugation at  
800 rpm at 4°C for 3 minutes. Finally, columns were  transferred to a new 1.5 ml reaction tube 
(Eppendorf) and elution was performed by adding 100 µl histone elution buffer and 
centrifugation at 800 rpm at 4°C for 3 minutes. To further purify the isolated histone proteins, 
6 µl 70% perchloric acid (Sigma) were added to precipitate histone proteins over night at 
4°C. The following day, samples were centrifuged at  13300 rpm at 4°C for at least 1 hour and 
pelleted histones were washed with 1 ml ice cold 4% perchloric acid followed by 
centrifugation at 13300 rpm at 4°C for 5 minutes. T wo additional washing steps with ice cold 
acetone (Sigma) containing 0.2% HCl and pure acetone were carried out before drying the 
pellet at room temperature. Finally, the histone pellet was resuspended in at least 100 µl H2O 
(Braun Biotech) and stored at 4°C.     
3.2.20 Western Blot Analysis 
Electrophoretic separation of protein samples was performed by using 4-12% gradient 
NuPAGE Bis-Tris Precast Gels (Life Technologies) with a maximum loading capacity of 20 µl 
(12 well; 1mm). First, protein samples were mixed with 1:3 volume NuPAGE LDS Sample 
Buffer (4x) (Life Technologies) followed by denaturation at 95°C for 5 minutes. Together with 
protein samples, 10 µl Spectra multicolor broad range ladder (Fermentas) was loaded to the 
gel and protein separation was carried out in 1x NuPAGE Running Buffer (Life 
Technologies), which was partially mixed with NuPAGE Antioxidant (Life Technologies). Gel 
electrophoresis was performed at 140 V for 75 minutes. Afterwards, separated proteins were 
transferred to a polyvinylidene fluoride (PVDF) membrane (Sigma) by a full wet blotting 
procedure using a Mini Protean Gel Transfer system (Biorad), Western blot transfer buffer  
and a stepwise increasing current (100 mA for 10 minutes, 200 mA for 10 minutes, 300 mA 
for 10 minutes 400 mA for 10 minutes 500 mA for 10 minutes). Subsequently, PVDF 
membranes were blocked in TBS-T containing 3% bovine serum albumin (BSA) (Sigma) and 
10% milk (Roth). If required, NuPAGE gels were coomassie stained by using ProtoBlue Safe 
(National Diagnostics). Primary antibodies were diluted as indicted in 3.1.1 in 10% blocking 
solution in TBS-T and incubated with the membrane over night at 4°C with constant rolling. 
After three washing steps with TBS-T at room temperature for 5 minutes, horseradish 
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peroxidase (HRP) coupled secondary antibodies were applied at room temperature for at 
least 1 hour with constant rolling. Chemiluminescent detection using ECL or ECLplus (GE 
Healthcare) and X-ray films (FUJI) was performed as described in the manufacturer’s 
protocol. Hereby, exposure time was individually adjusted.  
3.2.21 Gene Expression Profiling 
Genome-wide mRNA expression profiling was performed by isolating high quality RNA from 
SF188 glioblastoma cells. Sample library preparation, hybridization and quality control was 
carried out at the Microarray Department of the University of Amsterdam (Netherlands) using  
the Affymetrix GeneChip® Human Genome U133 Plus 2.0 Array according to manufacturer’s 
instructions.  
3.2.22 DNA Methylation Analysis 
More than 450,000 single CpG sites per DNA sample were analyzed for their methylation 
status using the Infinium HumanMethylation450 BeadChip (Illumina) and high quality 
DNA isolated from transduced SF188 cells. Bisulfite conversion, array hybridization and 
data normalization was performed by the Genomics & Proteomics Core Facility of the 
German Cancer Research Center (DKFZ) (Heidelberg) according to standardized 
protocols.   
3.2.23 Immunohistochemistry (IHC) 
Protein expression analysis by immunohistochemistry was performed by staining a custom-
made tissue microarray (TMA) of pediatric GBM samples. For all tissue cores, regions 
representing neoplastic tissue were identified by hematoxylin and eosin staining  
(HE staining). As a control, non-neoplastic reference tissue cores were stained in parallel. 
Immunohistochemistry was performed based on an indirect streptavidin-biotin method. The 
TMA containing 10 µm sections was deparaffinized using xylene two times for 5 minutes. 
Rehydrating was performed by an ethanol series (100%, 96%, 70%: 2 minutes each). 
Epitopes were uncovered by applying pre-heated citrate buffer (pH 6.0) and heating in a 
microwave oven (400 W for 10 minutes). Inhibition of endogenous peroxidase activity was 
accomplished by incubation with 3% hydrogen peroxide (Dako) followed by incubation (4°C 
overnight in a wet chamber) with primary antibodies diluted 1:1000 in antibody diluent 
(Dako). The next day, tumor cores were incubated with horseradish peroxidase (HRP) 
conjugated streptavidin (Dako) at room temperature for 15 minutes. Finally, slides were 
stained with diaminobenzidine hydrochloride (DAB) supplemented with hydrogen peroxide 
followed by counterstaining with hematoxylin and mounting. 
Immunopositivity was evaluated by Prof. Andrey Korshunov (Clinical Cooperation Unit 
Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany).  
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3.2.24  Cloning of C-terminally HA-tagged H3.3 RCAS Constructs 
Retroviral overexpression of H3.3 variants in the brain of neonatal mice required cloning of 
H3.3 variants into the RCASBP(A) plasmid. PCR amplification using GoTag DNA 
polymerase (Promega) was carried out using primers H3.3-NotI-for/H3.3-HA-ClaI-rev 
(annealing temperature 58°C; 60 seconds extension t ime at 72°C) and H3.3 overexpression 
constructs (pcDNA_H3.3-WT-HA, pcDNA_H3.3-K27M-HA, pcDNA_H3.3-G34R-HA) as a 
template to introduce NotI and ClaI restriction sites. Purified PCR product was cloned into the 
pJet1.2 plasmid using the CloneJet PCR cloning kit (Thermo Scientific), followed by 
sequence verification using Sanger sequencing. Afterwards, H3.3-pJet1.2 constructs 
(pJet1.2_H3.3-WT-HA, pJet1.2_H3.3-K27M-HA, pJet1.2_H3.3-G34R-HA) were double-
digested with restrictions enzymes NotI and ClaI (NEB). After gel extraction using the 
QIAquick Gel Extraction Kit (Qiagen), NotI/ClaI digested inserts were ligated into NotI/ClaI 
linearized RCASBP(A) using T4 DNA ligase (Roche) followed by Sanger sequencing.   
3.2.25 Cloning of C-terminally AU1-tagged dnTP53 RCAS Constructs 
Dominant-negative p53 (dnTP53) construct (MSCV-dnTP53) was kindly provided by Prof. 
Rob Wechsler-Reya (Sanford-Burnham Medical Research Institute, La Jolla, USA). DnTP53 
ORF was amplified using GoTaq DNA polymerase (Promega) with primers dnTP53-NotI-
for/dnTP53-AU1-rev (annealing temperature 60°C; 30 seconds extension time at 72°C) 
introducing an amino terminal NotI restriction site and a C-terminal AU1 tag. After PCR 
purification (Norgen PCR purification kit), the PCR product was cloned into the mammalian 
overexpression vector pcDNA3.1 (Life Technologies) followed by transformation into 
OneShot TOP10 competent E. coli cells (Life Technologies). Single clones were subjected to 
Sanger sequencing to confirm the integrity of pcDNA_dnTP53-AU1. Afterwards, a C-terminal 
ClaI restriction site was introduced by PCR amplification using GoTaq DNA polymerase and 
primers dnTP53-NotI-for/dnTP53-AU1-ClaI-rev (annealing temperature 60°C; 30 seconds 
extension time at 72°C). Purified PCR product was d ouble-digested with restrictions 
enzymes NotI and ClaI (NEB) and ligated into NotI/ClaI digested RCASBP(A) using T4 DNA 
ligase (Roche) followed by Sanger sequencing.  
3.2.26 Restriction Digestion 
Digestion of plasmid DNA with restriction enzymes ClaI and NotI (NEB) was performed at 
37°C overnight. In a 1.5 ml reaction tube, 5 µl Cla I (5 U/µl), 5 µl NotI (5 U/µl) and 10 µl NEB 
buffer 4 (5x) (NEB) were given to 20 µg plasmid DNA in a total volume of 50 µl H2O (Braun). 
Digestion of plasmid DNA with restriction enzymes XhoI and XbaI (Fermentas) was 
performed at 37°C for 2 hours. In a 1.5 ml reaction  tube, 5 µl XhoI (10 U/µl), 5 µl XbaI (10 
U/µl) and 5 µl tango buffer (10x) (Fermentas) were given to 20 µg plasmid DNA in a total 
volume of 50 µl H2O (Braun). 
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3.2.27 Retroviral Gene Transfer using RCAS/Ntv-a System 
Retroviral particles harboring HA-tagged H3.3 variants or dnTP53-AU1 were generated by 
transfection of DF1 chicken fibroblasts (ATCC) with RCASBP(A) constructs. Low passage 
DF1 cells (passage number < 5) were seeded the day before transfection in a 10 cm cell 
culture dish (TPP) and maintained in DMEM media (ATCC) supplemented with 10% FCS 
(ATCC) in a humidified 39°C incubator with 5% CO 2. Transfection was conducted by using 
10 µl FuGENE HD transfection reagent (Roche) and 4 µg plasmid DNA in a total volume of 
200 µl OptiMEM medium (Life Technologies). After formation of transfection complexes at 
room temperature for 20 minutes, solution was given to the cells in a dropwise manner. 
Transfection efficiency was monitored every 24 hours by performing parallel transfection 
experiments with RCASBP(A) harboring the green fluorescent protein (GFP) and 
fluorescence microscopy. 72 hours after transfection, DF1 cells were washed with PBS (Life 
Technologies) and pelleted by trypsination and centrifugation at 800 rpm at room 
temperature for 5 minutes. After cell counting using a ViCell XR cell counter (Beckmann), 
virus producing DF1-cells were diluted to a final concentration of 40,000 cells/µl in  DMEM 
media (ATCC). All intracranial injections were performed with virus producing DF1 cells 72h 
post transfection and neonatal Ntv-a mice as previously described [156].  
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4 RESULTS 
4.1 Expression of Mutant Histone H3.3 in Primary Glioblastoma 
By performing whole-genome or whole-exome sequencing, our laboratory and others 
identified two recurrent mutations (K27M or G34R) within the H3F3A gene, coding for the 
replication-independent histone H3.3 in pediatric glioblastoma [30, 49]. To date, H3F3A 
mutations were identified in approximately 50% of all analyzed childhood GBMs with a 
patient age younger than 22 years. Mutations of the second H3.3 producing gene H3F3B 
were not found. With the exception of one single K27M mutated tumor, all identified H3F3A 
alterations are heterozygous mutations, affecting only one H3F3A allele. Assuming biallelic 
expression of the H3F3A gene, this would lead to 50% mutated H3.3 mRNA and 
consequently H3.3 protein.  
In order to test for biallelic expression of H3F3A in H3.3 mutated tumors, RNA of 6 pedGBM 
samples harboring either the K27M (n=3) or G34R (n=3) mutation was isolated and 
transcribed into cDNA. After PCR amplification of a fragment covering both mutations, PCR 
products were cloned into the pGEM-T Easy vector system. Twenty clones per tumor were 
analyzed by Sanger sequencing using vector specific primers. Thus, the percentage of 
mutated clones identified directly reflects the relative expression of the mutated H3F3A allele 
in the tumor. In all analyzed tumors the number of mutated clones was between 15 and 70%. 
Assuming a high tumor cell content within the tumor mass originally used for RNA extraction, 
these results reflect biallelic expression of the H3F3A gene in pedGBMs. 
Whole-transcriptome sequencing data of one K27M and two G34R mutated GBMs were 
used to confirm that both alleles of the H3F3A gene are expressed in primary tumors. In the 
K27M mutated tumor, 138 sequencing reads were generated covering the respective codon 
within the H3F3A transcript. While 109 reads supported the wildtype codon GGG, coding for 
lysine at amino acid position 27 of H3.3, 29 reads (21%) showed the mutated codon AGG, 
replacing lysine by methionine at the respective amino acid position. In both G34R mutated 
tumors the relative number of RNA sequencing reads supporting the G34R mutation was 
57% and 37%. This clearly indicates that tumor cells harboring a heterozygous H3F3A 
mutation still express approximately the same amount of wildtype H3.3 from the second 
(unaffected) H3F3A allele.   
The total amount of mutated H3.3 protein can be further diluted by wildtype H3.3 protein, 
which is produced from the second H3.3 producing gene H3F3B. For this reason relative 
mRNA expression of H3F3A and H3F3B was analyzed by quantitative real-time PCR (qRT-
PCR) in three K27M and three G34R mutated pedGBMs. As illustrated in Figure 5A, both 
H3.3 producing genes (H3F3A and H3F3B) are expressed in primary GBMs harboring H3.3 
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mutations. With the exception of one G34R mutated GBM (GBM5), relative mRNA 
expression levels of both genes were comparable.   
Additionally, H3F3A/B mRNA levels were analyzed by using whole-genome expression 
profiling data of 81 GBM samples with known H3.3 mutation status. This data confirms the  
qRT-PCR results, as both H3.3 coding genes are found to be transcribed into mRNA. By 
trend, H3F3A showed slightly higher expression levels compared to the H3F3B gene  
(Figure 5B). The trend towards higher H3F3B expression in G34R mutated tumors measured 
by qRT-PCR is not confirmed by the microarray data. Furthermore, mRNA expression of 
H3F3A and H3F3B in K27M (n=14) and G34R (n=11) mutated tumor samples is comparable 
to tumors without H3F3A mutations (n=56), speaking against compensatory effects as a 
consequence of H3F3A mutations.  
 
 
Figure 5. H3F3A and H3F3B mRNA Expression in primary GBM Tumors. (A) Messenger RNA 
expression of both H3.3 producing genes (H3F3A and H3F3B) in H3.3-K27M (n=3) and H3.3-G34R 
(n=3) mutated pedGBM samples was measured by quantitative RT-PCR. Relative gene expression is 
normalized to the housekeeping gene SDHA. (B) Affymetrix microarray expression data is visualized 
as boxplots to compare mRNA expression levels of both H3.3 coding genes in 81 primary GBM 
samples. Tumors were grouped according to their H3F3A mutation status (H3.3-WT (n=56), 
H3.3-K27M (n=14) or H3.3-G34R (n=11)). (Affymetrix probe set ID used for H3F3A expression: 
211940_x_at. Affymetrix probe set ID used for H3F3B expression: probe 211999_at.) 
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In summary, biallelic expression of the H3F3A gene in combination with similar 
transcriptional output of both H3.3 encoding genes (H3F3A and H3F3B) results in the fact 
that approximately 25% of total H3.3 protein within H3.3 mutated tumor cells harbors the 
respective H3.3 mutation. In other words, the complex genetic and epigenetic changes 
originally identified in H3.3 mutated tumors are induced by a relatively low amount of mutant 
protein, indicating a dominant negative effect. 
No differences in mRNA expression of canonical histone H3 was detected in K27M or G34R 
mutated pedGBMs compared to tumors without H3F3A mutations (Supplementary Figure 1). 
Microarray expression data of other histone H3 variants such as H3.4, H3.5, H3.X or H3.Y 
was not available since these genes are not covered by the Affymetrix microarray platform.   
  
4.2 Incorporation of mutant H3.3 Protein 
The non-canonical histone variant H3.3 has been reported to be enriched at transcriptionally 
active genes in several cell types [157-160]. In order to find out whether the identified H3.3 
mutations affect the incorporation of histone H3.3 protein into chromatin, SF188 glioblastoma 
cells were transfected with EGFP-tagged H3.3 variants (H3.3-WT-EGFP, H3.3-K27M-EGFP 
and H3.3-G34R-EGFP). Afterwards, H3.3 protein localization was visualized by fluorescence 
microscopy 96 hours after transfection. As a result, wildtype H3.3 protein but also K27M or 
G34R mutated H3.3 exclusively showed nuclear localization as indicated by co-localization 
with blue DAPI signals (Figure 6). 
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Figure 6. Localization of mutant Histone H3.3 Protein. Protein localization of EGFP tagged H3.3 
variants (H3.3-WT-EGFP, H3.3-K27M-EGFP, H3.3-G34R-EGFP) was analyzed by fluorescence 
microscopy 96 hours after transfection of SF188 cells. Nuclear localization of H3.3 variants (green 
EGFP signal) is indicated by co-localization with nuclear DNA, labeled with 4',6-diamidino-2-
phenylindole (DAPI) (blue signal). Asterisk marks an untransfected SF188 cell without H3.3-K27M-
EGFP expression. 
 
To determine whether protein localization of mutant H3.3 within the cell nucleus differs from 
wildtype H3.3 localization, SF188 cells expressing CFP tagged wildtype H3.3 were 
transfected simultaneously with EGFP tagged H3.3 harboring either the K27M or G34R 
mutation. Localization of both fluorescently tagged H3.3 proteins was analyzed by two-
channel fluorescence confocal imaging. In doing so, protein co-localization was quantified by 
measuring the extent of signal overlap between wildtype H3.3 (CFP: red signal) and K27M or 
G34R mutated H3.3 (EGFP: green signal) (Figure 7). The extent of signal overlap between 
CFP tagged wildtype H3.3 protein and EGFP tagged wildtype H3.3 served as a positive 
control. Co-localization of both wildtype proteins was demonstrated by high correlation 
coefficients (R2>0.95) (Figure 7A). Correlation analysis of wildtype H3.3 and one of the 
mutant histones (K27M or G34R) did not show any significant differences in protein 
localization, indicated by equally high correlation coefficients (Figure 7B/C). Alternatively, the 
indistinguishable protein localization of wildtype and mutant histone H3.3 is illustrated by 
almost identical signal intensity profiles of both color channels. Based on these results, 
fundamental differences in mutant histone nuclear transport or histone protein incorporation 
can be ruled out. 
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Figure 7. Incorporation of mutant H3.3 Protein. SF188 glioblastoma cell were co-transfected  for 96 
hours with CFP tagged wildtype H3.3 (red signal) and one of the following EGFP-tagged variants 
(green signal): H3.3-WT-EGFP (A), H3.3-K27M-EGFP (B) or H3.3-G34R-EGFP (C). Scatter plots 
show pixel distribution, whereby the intensity of a given pixel of the EGFP signal corresponds to the  
 46 RESULTS 
x-coordinate and the intensity of the corresponding pixel of the CFP signal is shown as the  
y-coordinate. Correlation was done in the area delineated using 10 confocal images per cell nucleus 
(5 cell nuclei/experiment). High correlation coefficients (R2) indicate high signal overlap between 
wildtype CFP tagged H3.3 and the respective EGFP tagged H3.3 variant. Signal intensity plots (lower 
part of each experiment) show the intensity of the CFP and EGFP signal along the distance in the 
designated rectangle within the cell nucleus. 
 
 
Due to the signal density in combination with the limited resolution of quantitative confocal 
imaging of fluorescently labeled proteins, this technique is not able to reveal more detailed 
differences in mutant H3.3 localization. Therefore, a comprehensive high-resolution map of 
H3.3 incorporation sites was generated by performing chromatin immunoprecipitation (ChIP) 
followed by next generation sequencing. By using a tag-specific antibody, which allows 
immunoprecipitation of ectopic HA-tagged variants of H3.3, genome-wide incorporation maps 
of K27M mutant, G34R mutant and wildtype H3.3 protein were generated in transduced 
SF188 glioblastoma cells. Sequencing of DNA fragments bound to one of the three H3.3 
variants (referred to as IP) produced a minimum of 3.67x106 sequencing reads. For 
normalization, input samples of each ChIP experiment were sequenced in parallel, leading to 
a minimum of 4.29x106 sequencing reads.  
In order to compare the ChIP-Seq profiles of mutated H3.3 and wildtype H3.3, the human 
genome was divided into 10 kb non-overlapping windows (also called bins). Higher resolution 
data analysis using smaller bins (e.g. 5 kb) was not possible without increasing the 
sequencing depth. In average, 51 reads were located within one 10 kb bin. Data was 
normalized by dividing read numbers within a particular 10 kb bin of the IP experiments by 
the read number within the respective bin of the input sample. Afterwards, normalized ChIP-
Seq profiles of one of the two mutants K27M or G34R were compared to profiles of wildtype 
H3.3. Finally, results were illustrated as ratio plots for each of the human chromosomes, as 
this figure type visualizes aberrant incorporation of mutant histone H3.3 protein. As shown for 
K27M and G34R mutant H3.3 in Figure 8A and Figure 8B respectively, the log2 ratio of 
normalized ChIP-Seq reads between mutant and wildtype H3.3 mainly did not exceed +/-1, 
indicating very similar incorporation sites of both proteins based on 10 kB resolution. 
Genomic bins showing more prominent differences between mutant and wildtype H3.3 
deposition were found in pericentromeric regions of several chromosomes like chromosome 
1, chromosome 9 or chromosome 14. This was of particular interest, as Histone H3.3 has 
been shown to be preferentially incorporated at pericentromeric heterochromatin. In addition, 
we found some genomic regions such as a region on chromosome 5q, where differences 
between mutant and wildtype H3.3 incorporation seemed to be more striking. Careful 
revision of ChIP-Seq data revealed that these genomic regions of differential H3.3 
incorporation were poorly covered by sequencing reads. In line with this, sequencing gaps 
were causative for differential incorporation of mutant H3.3 at pericentromeric DNA. These 
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regions are known to be poorly covered by next-generation sequencing techniques due to 
their high repetitive complexity. Taken together, no differences between incorporation sites of 
mutant and wildtype H3.3 have been identified by performing ChIP-Seq of epitope tagged 
H3.3 mutants in SF188 glioblastoma cells at the resolution chosen. 
 
A 
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Figure 8. Incorporation Profiles of mutant Histone H3.3. SF188 glioblastoma cells stably 
expressing epitope-tagged H3.3 variants (H3.3-WT-HA, H3.3-K27M-HA, H3.3-G34R-HA) for 14 days 
were used to perform chromatin immunoprecipitation with an epitope-specific antibody followed by 
next generation sequencing (ChIP-Seq). Data is illustrated as ratio plots comparing normalized ChIP-
Seq profile of the K27M (A) or G34R (B) mutant with ChIP-Seq profiles of wildtype H3.3. Each dot 
represent a genomic region of 10 kB.  
 
 
4.3 Overexpression of mutant Histone H3.3 
To find out if overexpression of mutant histone H3.3 is sufficient to induce similar effects on 
DNA methylation and gene expression, which have been originally described in primary 
pedGBMs, isogenic SF188 glioblastoma cells were generated, stably overexpressing either 
K27M or G34R mutated H3.3. Although the contribution of mutations within the H3.3 
chaperone ATRX and the tumor suppressor p53 in initiation and progression of H3.3 mutated 
GBMs is not elucidated yet, high co-incidence rates of H3.3 mutations and mutations within 
ATRX and TP53 indicate the importance of these additional genetic hits [30]. In order to 
recapitulate the genetic background of H3.3 mutated primary GBMs in vitro, SF188 
glioblastoma cells were chosen for further examinations. SF188 cells are derived from a 
male 8-year old patient suffering from a highly aggressive glioblastoma, harboring several 
genetic alterations including a mutation within the TP53 gene [161-163].  
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For subsequent overexpression experiments, the open reading frame of wildtype H3.3 as 
well as K27M or G34R mutated H3.3 was cloned in frame with a C-terminal HA-tag into the 
lentiviral overexpression vector pLVX-Puro. After lentivirus production, SF188 glioblastoma 
cells were transduced and the expression of exogenous H3.3 variants was analyzed by 
Western blot. Due to the high abundance of endogenous H3.3 protein, expression of 
exogenous/overexpressed H3.3 only accounts for approximately 5-10% of total H3.3 protein 
(Figure 9A). 
To assess, whether overexpression of mutant H3.3 induces changes in cell viability or growth 
characteristics of SF188 cells, cell cycle analysis and a proliferation assay was conducted. 
Cell proliferation of mutant H3.3 overexpressing SF188 cells was analyzed by performing 
MTS assays using the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay 
(Promega). Seven days after transduction, SF188 cells were seeded and readout was 
carried out another 24 hours later. Mutant as well as wildtype H3.3 overexpressing cells 
showed reduced cell proliferation compared to empty vector (EMPTY-pLVX) transduced cells 
(Figure 9B). K27M expressing cells showed a trend towards slightly higher proliferation, while 
mutant G34R expressing cells proliferated slower without reaching significance.  
Furthermore, the cell cycle of transduced SF188 cells was analyzed by using a propidium 
iodide (PI) flow cytometric assay originally described by Nicoletti et al. [155]. Seven days 
after transduction, SF188 cells were seeded and incubated for additional 24 hours followed 
by flow cytometric analysis. As illustrated in Figure 9C, the number of apoptotic cells 
represented by the SubG1 fraction was marginally reduced in K27M expressing cells 
compared to wildtype and G34R expressing cells. Less apoptotic cells might also explain the 
slightly increased number K27M transduced cells in the MTS assay. In addition, the number 
of cells preparing for mitosis in G2 phase was slightly increased in K27M transduced cells, 
resembling SF188 cells transduced with the empty vector control. In conclusion, SF188 
glioblastoma cells overexpressing mutant H3.3 did not show fundamental differences in cell 
cycle distribution compared to wildtype H3.3 overexpressing cells.  
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Figure 9. Overexpression of Histone H3.3 Mutants in SF188 Cells. (A) Western blot analysis 
showing overexpression of HA-tagged H3.3 variants (H3.3-WT-HA, H3.3-K27M-HA, H3.3-G34R-HA) 
by using an HA-specific antibody. H3.3 Western blot results illustrate the relative amount of 
overexpressed H3.3 protein, which is visible as a faint band above the endogenous H3.3 protein. (B) 
Cell proliferation of SF188 cells overexpressing mutant H3.3 was assessed by MTS assay 8 days after 
transduction. (C) Propidium iodide assay of H3.3 variant overexpressing cells displays marginal 
differences in cell cycle progression of K27M expressing cells at the same time point.   
 
 
PedGBMs expressing one of the two H3.3 mutants were reported to be characterized by 
distinct gene expression and DNA methylation profiles [30, 48]. Differential expression of 
marker genes OLIG1/2 and FOXG1 was shown to robustly identify K27M or G34R mutated 
samples. Moreover, promoters of OLIG1/2 and FOXG1 were found to be differentially 
methylated in these tumors. For this reason, SF188 cells, transduced for 25 days to 
overexpress mutant H3.3, were profiled by whole-genome gene expression and DNA 
methylation arrays using the Human Genome U133 Plus 2.0 Array (Affymetrix) and the 
Infinium Methylation 450K Array (Illumina), respectively. In line with published results, OLIG1 
mRNA expression was also downregulated in H3.3-G34R overexpressing SF188 cells. 
However, hypermethylation of the OLIG1 promoter region was not detected (Figure 10A). 
OLIG2, which was specifically downregulated in G34R mutated primary tumors, did not show 
differential expression or DNA methylation (Figure 10B). Compared to more distal parts of 
the OLIG1/2 gene bodies, DNA methylation was substantially reduced in close vicinity to the 
transcriptional start sites and the adjacent part of the gene body. In contrary to the findings in 
K27M mutated pedGBMs, downregulation of FOXG1 expression due to promoter 
hypermethylation was not detected in SF188 cells overexpressing the K27M mutant (Figure 
10C). Accordingly, gene promoters of additional genes such as SOX10, ZNF233, LYPD1 or 
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IRX1, which displayed differential methylation in primary tumors, did not show methylation 
differences at this early time point after transduction.   
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Figure 10. Promoter Methylation and mRNA Expression of OLIG1/2 and FOXG1.  
DNA methylation in transduced SF188 cells at the genomic locus of OLIG1 (A), OLIG2 (B) and 
FOXG1 (C) is shown on the left side. DNA methylation levels (0-100%) of single CpGs are indicated 
by the height of vertical bars. Bar charts on the right illustrate mRNA expression of OLIG1/2 and 
FOXG1 in transduced SF188 cells.   
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4.4 Combined Knockdown and Overexpression Experiments  
As shown for transduced SF188 glioblastoma cells, the amount of endogenous wildtype H3.3 
exceeds the amount of overexpressed mutant H3.3 protein at least 10 fold  
(see also Figure 9A). In contrast, the relative amount of mutant H3.3 in primary pedGBM 
samples with H3F3A mutations represents 25% of total H3.3 protein. To increase the relative 
amount of ectopic mutant H3.3 compared to endogenous wildtype H3.3, a combined 
knockdown and overexpression approach was performed. As confirmed by gene expression 
data of transduced SF188 cells described in 4.3, H3.3 expression in (transduced) SF188 
cells is driven from both endogenous H3.3 genes to an almost identical extent. 
Consequently, the expression of both H3.3 coding genes had to be silenced by different 
short hairpin RNAs (shRNAs) to reduce the overall amount of endogenous H3.3 protein. 
Three shRNAs targeting the untranslated region (UTR) of H3F3A (shH3F3A_1; shH3F3A_2 
and shH3F3A_3) and two shRNAs targeting the UTR of H3F3B (shH3F3B_1 and 
shH3F3B_2) were tested for their knockdown efficiency in SF188 cells by measuring H3F3A 
or H3F3B mRNA expression by quantitative realtime PCR (qRT-PCR) using H3F3A or 
H3F3B specific primers (H3F3A for/rev or H3F3B for/rev). Compared to the non-target 
shRNA (NT-shRNA), SF188 cells transduced with one of the five specific shRNAs showed a 
significant mRNA downregulation of the respective gene (Figure 11A/B). While shH3F3A_1 
led to a reduction of H3F3A mRNA expression by 90%, shH3F3B_2 reduced the H3F3B 
mRNA level by 85%. 
As expected, simultaneous transduction of SF188 cells with lentiviral particles delivering 
shH3F3A_1 and shH3F3B_2  leads to a significant downregulation of overall H3.3 mRNA 
levels as detected by qRT-PCR using H3F3A/B specific primers (H3F3A/B for & H3F3A/B 
rev) (Figure 11C). Moreover, downregulation of total H3.3 protein in these cells was 
confirmed by Western blot analysis (Figure 11D). 
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Figure 11. Knockdown of endogenous H3.3 in SF188 Cells. QRT-PCR results illustrating  
H3F3A (A) and H3F3B (B) mRNA expression upon lentiviral delivery of different shRNA constructs 
targeting the UTR of H3F3A or H3F3B. Relative gene expression is normalized to the housekeeping 
gene SDHA. H3F3A/B expression in SF188 cells simultaneously transduced with two different 
shRNAs targeting both H3.3 producing genes was evaluated by qRT-PCR (C) and Western blot 
analysis (D). By using shH3F3A_1 and shH3F3B_2, total H3.3 protein level was downregulated to 
approximately 15%. 
 
 
As reported for MCF7 human breast adenocarcinoma cells, inhibition of H3.3 expression 
may alter cell proliferation in vitro [164]. Based on this finding, cell cycle analysis of SF188 
cells transduced with different combinations of shRNAs targeting endogenous H3F3A and 
H3F3B was carried out by performing the propidium iodide assay. The results indicate that 
knockdown of H3.3 expression in SF188 cells did not induce any change in cell cycle 
progression (Figure 12).  
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Figure 12. Cell Cycle Analysis in SF188 Cells upon H3.3 Knockdown. SF188 glioblastoma cells 
were transduced with different combinations of shRNAs targeting endogenous H3F3A or H3F3B for 14 
days. Propidium iodide assay was conducted to compare cell cycle distribution of H3.3 knockdown 
cells to cells transduced with a non-target shRNA (NT).    
 
 
Knockdown of endogenous H3.3 and simultaneous overexpression of mutant H3.3 requires 
two separate rounds of transduction. A simultaneous transduction with lentiviral particles 
delivering (i) the shRNA targeting H3F3A (ii) the shRNA targeting H3F3B and (iii) the 
respective H3.3 overexpression construct was not favored in order to avoid high virus loads 
resulting in cytotoxicity. As both lentiviral constructs, which were used to deliver shRNAs 
(pLKO.1-puro) or overexpression constructs (pLVX-puro), provide puromycin resistance to 
transduced cells, efficiency of the second round of transductions was of particular 
importance. Evaluation of transduction efficiencies in SF188 cells was conducted by using 
GFP overexpressing pLVX-Puro constructs followed by flow cytometry detecting GFP-
positive cells. Using a MOI of 5, more than 90% of SF188 cells were detected to express 
GFP (Figure 13).  
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Figure 13. Transduction Efficiency in SF188 Glioblastoma Cells. SF188 cells were treated with 
lentiviral particles (MOI 5) resulting in expression of GFP. Percentage of GFP positive (transduced) 
cells was analyzed by flow cytometry three days later showing more than  
90% GFP positive cells (right) compared to empty vector transduced cells (left).  
 
   
The first round of transduction on SF188 cells was carried out to reduce the expression of 
endogenous H3.3 followed by selection with 3 µg/ml puromycin for 3 days. Afterwards, 
SF188 cells were treated with lentiviral particles mediating mutant H3.3 overexpression. 
Overall H3.3 mRNA expression (H3F3A and H3F3B transcripts) was measured by qRT-PCR 
7 days after the second round of transductions. Compared to the non-target shRNA (NT-
shRNA), H3.3 levels were significantly reduced in all SF188 cells treated with shRNAs 
targeting the UTR of H3F3A and H3F3B (shH3F3A_1 and shH3F3B_2) (Figure 14). SF188 
cells additionally transduced with H3.3 overexpression constructs showed higher expression 
of H3.3 mRNA compared to empty vector or GFP transduced controls. However, the shRNA 
induced knockdown had stronger (down)regulatory effects on H3.3 expression compared to 
the H3.3 overexpression (Figure 14). Molecular characterization of SF188 cells combining 
knockdown of endogenous H3.3 and overexpression of one of the two mutants is subject to 
further studies. 
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Figure 14. Combined Knockdown and Overexpression Experiments. Quantitative RT-PCR was 
conducted to determine H3.3 mRNA expression in SF188 cells transduced with shRNA targeting 
endogenous H3.3 (shH3F3A_1 & shH3F3B_2) and simultaneous overexpression of H3.3 variants 
(H3.3-WT-HA, H3.3-K27M-HA, H3.3-G34R-HA). Relative gene expression is normalized to the 
housekeeping gene SDHA. While down-regulatory effects are compared to a NT-shRNA, 
overexpression was normalized to an empty control vector (pLVX-EMPTY).   
 
 
4.5 The Key Epigenetic Mark H3K27me3 in H3.3 mutant GBMs 
Preliminary work of our laboratory indicated that each H3.3 mutation (K27M or G34R) 
defines an epigenetic subgroup of pedGBMs with a distinct gene expression and global DNA 
methylation pattern [30, 48]. Therefore, H3.3 mutated pedGBMs were analyzed for several 
posttranslational modifications, which are known to substantially influence chromatin 
structure and consequently gene expression [165]. Immunohistochemistry (IHC) was 
performed on 27 pedGBM tumors with known H3F3A mutation status. IHC staining was 
conducted for repressive histone marks including H3K9me3 and H3H27me3 as well as for 
the activating histone marks H3K4me3 and H3K36me3. While all 27 tumors showed 
immunopositivity for the two activating histone marks H3K4me3 and H3K36me3 and the 
repressive mark H3K9me3, all K27M mutated GBMs (n=8) showed absence or strong 
reduction of H3K27me3 expression (Figure 15A). The existence of H3K27me3 positive cells 
of blood vessels in the surrounding brain tissue further supports the fact, that H3K27me3 
expression is specifically lost in K27M mutated tumor tissue (personal communication  
Prof. Andrey Korshunov). In contrast, all analyzed wildtype H3.3 tumors (n=13) as well as 
G34R mutated tumors (n=6) showed strong H3K27me3 immunopositivity (Figure 15B). 
These results indicate a dominant negative effect of the K27M mutant protein, since the 
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methylation specific H3K27 antibodies detect global H3K27me3 levels, including methylation 
at the highly abundant canonical histone H3.1 and H3.2. 
To confirm the global reduction of H3K27 trimethylation in K27M mutated tumors by a 
different technique, histone proteins were isolated from additional pedGBM samples and 
subjected to H3K27me3 Western blot analysis. Thus, significantly lower K27 trimethylation 
levels were detected in the K27M mutated tumor compared to the G34R and wildtype tumor 
(Figure 15C). Moreover, an additional H3K27me3 specific antibody confirmed strong 
reduction of lysine 27 trimethylation in histone extracts of two independent K27M mutated 
pedGBM samples (Figure 15D). While K27 monomethylation (H3K27me1) did not show 
differences in expression, acetylation of lysine 27 (H3K27ac) was found to be increased in 
two K27M pedGBM samples (Figure 15E). These reciprocal changes in methylation and 
acetylation at H3K27 have been commonly described in literature [166, 167].   
 
 
Figure 15. H3K27me3 Expression in K27M mutant GBMs. (A) H3K27me3 immunohistochemical 
stainings of primary GBM tumor tissues show strong immunopositivity in the H3.3 wildtype tumor but 
absence of this histone mark in the tumor expressing the H3.3 K27M mutant. (B) Overview of 
immunohistochemical stainings for H3K27me3 in pedGBMs with different H3.3 mutation status.  
(C) Western blot results illustrating H3K27Me3 reduction in histone extracts of a primary K27M GBM 
sample. Histone H4 protein expression indicates equal protein loading amounts.  
(D) Reduction of H3K27me3 was confirmed in histone extracts of additional primary GBMs using a 
different H3K27me3 specific antibody for Western blot analysis. (E) Western blot results showing 
unaltered levels of H3K27me1 but upregulated H3K27 acetylation in K27M mutated GBMs.  
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Since trimethylation at lysine 27 is established by the histone methyltransferase EZH2 as the 
catalytic component of the multiprotein complex PRC2, microarray data of 81 GBMs with 
known H3.3 mutation status was used to determine whether H3H27me3 reduction in K27M 
pedGBMs is reflected by altered mRNA expression of PRC2 core components. In doing so, 
PRC2 components EED, SUZ12 and RBAP48 as well as the H3K27me3 specific 
methyltransferase EZH2 (and its close homolog EZH1) did not show altered mRNA 
expression in K27M tumors (n=14) compared to G34R (n=11) or wildtype H3.3 samples 
(n=56) (see Supplementary Figure 2A-E). Accordingly, the H3K27me3 mediating histone 
demethylase UTX (KDM6A) is not transcriptionally upregulated in K27M mutant pedGBMs 
(see Supplementary Figure 2F). 
Given that K27M mutant pedGBMs exhibiting low H3K27me3 expression also express a 
certain amount of wildtype H3.3 protein, Western blot analysis was carried out to elucidate if 
the global downregulation of H3K27 trimethylation can also be found in SF188 glioblastoma 
cells stably overexpressing the K27M mutant. However, Western blot analysis of H3K27me3 
did no show differences 6 days after transduction (Figure 16A). At this (early) time point, 
several readouts described in 4.3 also did not show any phenotypic difference in K27M 
overexpressing cells. To assess, whether K27M induced downregulation of H3K27me3 
expression might progress over time, transduced SF188 cells were cultivated for additional 
50 days (15 passages). Subsequently, H3K27me3 levels were again determined by Western 
blot analysis. As shown in Figure 16B, H3K27me3 levels were found to be significantly 
reduced in SF188 cells expressing the K27M mutant. To test, whether the downregulation of 
H3K27me3 can be recapitulated in vitro independently of the used cell line, HEK293 cells 
overexpressing the H3.3 K27M mutant for 50 days were subjected to H3K27me3 Western 
blot analysis. As shown in Figure 16C, K27M expressing HEK293T cells also express 
reduced levels of global H3K27me3.  
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Figure 16. H3K27me3 in K27M overexpressing Cell Lines. (A) Western blot of transduced SF188 
cells did not show differential H3K27me3 expression 6 days after transduction. (B) After 50 days 
K27M expressing SF188 cells exhibit a significant reduction of H3K27me3 levels as detected by 
Western blot analysis. (C) Reduced levels of H3K27me3 expression were detected on HEK293T cells, 
stably transduced to overexpress K27M mutant for 50 days.  
 
 
4.6 The Histone Tail of mutated H3.3 shows Differences in PTMs 
Changes in the balance and dynamics of histone posttranslational modifications directly 
influence the physicochemical properties of chromatin, resulting in chromatin 
(de)condensation and altered gene expression. For some PTMs it has been shown that they 
directly influence other PTMs at the same histone tail (cis crosstalk) or adjacent histone 
proteins (trans crosstalk). The crosstalk of PTMs was investigated directly at the  
amino-terminal tail of histone H3.3 and both H3.3 mutants. Discrimination of endogenous 
wildtype H3.3 (17 kDa) and overexpressed/exogenous H3.3 variants was ensured by 
transfecting EGFP-tagged H3.3 variants with a molecular weight of 47 kDa. Upon 
transfection of HEK293T cells, Western blot analysis was carried out to determine the 
expression of several key histone marks including H3K4me3, H3K9me3, H3K27me1, 
H3K27me3, H3K27ac, H3.3S31p  and H3K36me3. As expected, H3K27me3 expression at 
the tail of K27M mutated H3.3 was completely abolished by the presence of methionine 
(Figure 17A). Moreover, none of the K27M transfected cells displayed a global 
downregulation of H3K27me3 three days after transfection. The existence of methionine at 
position 27 did not eliminate the signal for other position 27 specific modifications such as 
H3K27 acetylation and H3K27 monomethylation. For H3K27me1 this might partially be 
explained by the structural similarity of methionine and monomethylated lysine  
(see also Figure 21). While K4me3 was not detected at overexpressed H3.3, expression of 
K9me3 was unaltered between the three H3.3 variants. In contrary, H3S31p levels were 
downregulated at G34R mutated H3.3 and to a minor extent at K27M mutated H3.3 tails 
(Figure 17A). The activating histone mark H3K36me3 was significantly reduced at the tail of 
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the G34R mutant compared to the expression at the tail of K27M and wildtype H3.3 protein 
(Figure 17A). Finally, differential expression of all PTMs originally identified in H3K293T cells 
was confirmed in SF188 cells overexpressing EGFP-tagged H3.3 variants (Figure 17B).  
Trimethylation of K36 at histone H3 protein is a key epigenetic modification, associated with 
active gene transcription. In subsequent experiments, global expression of H3K36me3, 
which is specifically downregulated at the tail of mutant histone H3.3, was analyzed by 
Western blot analysis in primary tumor samples. In doing so, H3K36me3 levels were found to 
be slightly downregulated in the tumor sample harboring a G34R mutation (Figure 17C).   
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Figure 17. Posttranslational Modifications at the Histone Tail of H3.3 Variants. (A) Western blot 
results of different PTMs at the amino-terminal tail of EGFP-tagged H3.3 variants in HEK293T cells. 
The expression of equal amounts of EGFP-tagged exogenous H3.3 (47kDA) is illustrated by GFP and 
H3.3 signals. (B) Western Blot results confirming differential expression of H3K27me3, H3.3S31p and 
H3K36me3 at the tail of H3.3 variants in SF188 glioblastoma cells. (C) Global H3K36me3 expression 
in primary GBMs detected by Western blot analysis. (D) Summary of histone modifications detected at 
the tail of overexpressed EGFP-tagged mutant H3.3. Expression is compared to levels detected at 
overexpressed wildtype EGFP-tagged H3.3.   
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4.7 Arginine 34 is posttranslationally modified at G34R mutated H3.3 
Posttranslational modifications of the H3.3 amino-terminal tail include methylation of lysine 
and arginine residues. At the histone tail of G34R mutated H3.3, glycine 34 is replaced by an 
arginine, which represents a potential new site of methylation. While methylation of lysines 
includes mono-, di- and trimethylation, arginine residues can be found in mono- or 
dimethylated state, although dimethylation can occur in symmetric (SDMAs) as well as in 
asymmetric conformation (SDMAs). To find out, whether arginine 34 at G34R mutated H.3.3 
is posttranslationally methylated, histone extracts of HEK293T cells overexpressing  
EGFP-tagged H3.3 variants were fractionated by reverse phase high-performance liquid 
chromatography (RP-HPLC). Subsequently, fractions containing the overexpressed H3.3 
variants were identified by Western blot analysis and histone proteins were digested into 
peptides by trypsin in gel digestion. Finally, mass spectrometry (MS) was applied to analyze 
the modification status of arginine 34 at G34R mutated H3.3. As a result, dimethylation of 
arginine 34 was identified at the tail of G34R mutant H3.3 (Figure 18). The determination of 
R34me2 conformation (symmetric or asymmetric dimethylation) is still ongoing as it requires 
synthetically generated peptides as reference molecules.  
 
 
Figure 18. Identification of R34 dimethylation at G34R mutant H3.3. Mass spectrum of a digested 
peptide of G34R mutant H3.3 (SAPSTGRVK: amino acid position 28-36) overexpressed in HEK293T 
cells, showing dimethylation at arginine 34. The x-axis shows mass divided by charge (m/z).   
 
Arginine methylation in humans is catalyzed by a family of up to 11 different arginine methyl 
transferases, which have been found frequently deregulated in human cancers [91]. To 
determine, whether expression of human PRMTs is altered in G34R mutated pedGBMs, 
expression profiling data of 81 GBMs with known H3F3A mutation status was analyzed. As a 
result, none of the 11 PRMTs was found to be specifically deregulated in G34R mutated 
tumors (see Supplementary Figure 3). 
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4.8 Tumorigenic Potential of mutated H3.3 in the Brain of neonatal Mice 
To study, whether mutated H3.3 is able to induce high-grade gliomas in vivo, retroviral gene 
transfer was performed using the RCAS/Ntv-a system to selectively overexpress H3.3 
mutants in neural progenitor cells in the brain of neonatal mice. Consequently, HA-tagged 
variants of H3.3 (H3.3-WT-HA, H3.3-K27M-HA or H3.3-G34R-HA) were cloned into the 
RCASBP(A) vector and transfected into DF-1 chicken fibroblasts. The production of 
infectious virus and the expression of HA-tagged H3.3 variants were confirmed by applying 
virus containing supernatant of transfected DF-1 cells to fresh DF-1 cells followed by 
Western blot analysis using a HA-specific antibody (Figure 19A). In addition, receptor-
mediated cell infection was confirmed by applying virus-containing supernatant to murine 
XFM cells, expressing the virus-entry mediating Tv-a receptor at the cell surface.  
Subsequently, virus producing DF-1 cells were injected into the brain of neonatal mice 
(maximum p3) expressing the Tv-a receptor from the nestin promoter (Ntv-a). Since K27M 
mutated GBMs were predominantly found in midline locations and G34R mutated GBMs are 
more prevalent in one of the two cerebral hemispheres, respective K27M or G34R 
transfected DF-1 cells were injected in midline or hemispheric parts of the mouse brain [48]. 
All injected animals were subjected to magnetic resonance imaging (MRI) every 4-8 weeks, 
displaying no tumors 7 months after injection of virus producing DF1 cells.  
As described earlier, a frequent co-occurrence of TP53 mutations is found in H3.3 mutant 
pedGBMs. All K27M mutated cases and approximately 67% of G34R mutated tumors had 
somatic mutations of TP53 [30]. To determine the role of the TP53 pathway in enhancing the 
tumorigenic potential of mutated H3.3, mutant H3.3 and a dominant-negative variant of TP53 
(dnTP53) were simultaneously overexpressed in the brain of Ntv-a mice. DnTP53 protein 
mainly consists of the TP53 tetramerization domain and has been shown to completely 
abolish endogenous TP53 function in vivo [168]. In order to inject dnTP53 together with H3.3 
mutants, dnTP53 was cloned into the RCASBP(A) vector and transfected into DF-1 chicken 
fibroblasts. To detect the dnTP53 protein in vivo (separately from HA-tagged H3.3 variants), 
a carboxy-terminal AU1 tag was fused, which has been shown to have superior 
characteristics compared to other small epitope tags, when performing immunohistochemical 
detection of transgenes after CNS gene transfer [169, 170]. Before injection, expression of 
AU1-tagged dnTP53 in transfected DF-1 cells was confirmed by Western blot analysis 
(Figure 19B). Finally, fresh DF-1 cells were co-transfected with the AU1-tagged dnTP53 
construct and one of the HA-tagged H3.3 variants. Injection of co-transfected DF-1 cells was 
again carried out in consideration of K27M or G34R relative tumor location (see above). A 
complete overview of all animals used for injection of mutated H3.3 and H3.3/dnTP53 co-
injections is given in Figure 19C. As a result, 4 weeks post injection, one K27M/dnTP53 and 
one G34R/dnTP53 injected animal developed a brain tumor (Figure 19D). However, one of 
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the control animals, injected with wildtype H3.3 in combination with dnTP53 developed a 
brain tumor in the same time period. All other animals were sacrificed 6 months after 
injection without showing any brain abnormalities.   
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Figure 19. In vivo tumorigenic potential of mutated H3.3. Western blot analysis showing protein 
expression of HA-tagged H3.3 variants (A)  and AU1-tagged dnTP53 (B) in transfected DF1 cells. (C) 
Overview of all in vivo experiments showing the respective construct, injection site, number of animals 
and the time point of tumor detection by MRI. (D) MRI images of brain tumors in mice after injection of 
the respective H3.3 variant and dnTP53.  
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5 DISCUSSION 
The discovery of histone H3.3 mutations in nearly 50% of childhood glioblastoma and the 
identification of H3.3 mutation specific epigenetic subgroups has revolutionized our 
understanding of this devastating brain tumor. The data presented in this thesis provides 
novel insights into the complex alterations of the histone code induced by H3.3 mutants. The 
described findings set the stage for the translation of molecular advances into improved care 
for patients with this deadly disease. 
5.1 Incorporation of mutant Histone H3.3 
Since the successful cloning of the green fluorescent protein GFP of the jellyfish Aequorea 
Victoria in 1992, fluorescently labeled proteins have been used intensively to visualize 
protein localization in vitro and in vivo [171, 172]. Shortly after, the first fluorescently labeled 
histone proteins were generated leading to the observation that the fusion of relatively large 
epitope tags like GFP did not interfere with histone incorporation into nucleosomes [173]. 
Furthermore, it was shown that fluorescently labeled histone proteins, such as EGFP-tagged 
histone H3.3, undergo regular posttranslational modifications [160].    
To determine whether the identified H3.3 mutations interfere with the nuclear import of the 
histone protein, EGFP-tagged variants of H3.3 were transfected into HEK293T or SF188 
cells. Fluorescence microscopy revealed that both H3.3 mutant proteins were located 
exclusively within the cell nucleus of transfected cells (Figure 6). This is in line with published 
literature showing that nuclear localization of histone H3 proteins is not abolished by 
mutations affecting the histone tail or mutations resulting in truncated histone proteins, which 
are completely devoid of the histone tail [158].   
Subsequent experiments were conducted to investigate potential spatial differences in the 
incorporation pattern of mutant H3.3 into chromatin. As an initial experiment, quantitative 
dual color fluorescence confocal imaging was applied to cells simultaneously expressing 
CFP-labeled wildtype H3.3 and one of the two H3.3 mutants tagged with EGFP. Data 
interpretation was performed by measuring the extent of signal overlap between both 
fluorophores. Recently, the same experimental setup was used to measure the degree of 
signal overlap between different fluorescently labeled histone proteins including H3.3. 
Moreover, this technique revealed that H3.3 is enriched in chromatin domains marked by 
activating histone modifications [160]. Based on the results presented here, no differences 
between mutant H3.3 and wildtype H3.3 localization were identified in SF188 glioblastoma 
cells. Although multichannel confocal imaging is a commonly used method in molecular 
biology to study the localization of distinct molecules in cellular environment, results might be 
misleading due to the limited spatial resolution of confocal microscopy of approximately  
250 nm, which is mainly hampered by diffraction [174]. Compared to that, a single 
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nucleosome containing the complete histone octamer has a diameter of approximately  
10 nm.    
In a subsequent experiment, genome-wide incorporation profiles of mutant H3.3 were 
generated by performing chromatin immunoprecipitation followed by next generation 
sequencing (ChIP-Seq). ChIP-Seq offers the possibility to create genomic maps of precise 
protein incorporation sites at high resolution [175]. Within recent years, this method has been 
widely used to increase our knowledge about H3.3 incorporation sites in different cell types 
of various species [176-178]. By using an antibody targeting the HA-tag of overexpressed 
histone H3.3, genome-wide maps of incorporation sites of H3.3 mutants were generated and 
compared to the ChIP-Seq profile of (overexpressed) wildtype H3.3. In doing so, no apparent 
differences in protein incorporation of mutant and wildtype H3.3 have been identified  
(Figure 8).  
Based on current literature, histone H3.3 is preferentially incorporated at sites of active 
transcription [157, 158, 179]. ChIP-Seq profiles illustrate that H3.3 is enriched at the 
transcriptional start site of actively transcribed genes but also in regions further downstream 
of the transcription termination signal [178]. At these sites, histone H3.3 is loaded onto DNA 
via the histone chaperone HIRA [122, 123]. Alternatively, H3.3 protein was found to be 
located at transcriptionally silent genomic regions at the telomeres and pericentromeric 
heterochromatin. Here, histone H3.3 is loaded onto DNA via an independent pathway 
including the chaperones ATRX and DAXX. A possible mechanism, how mutations of histone 
H3.3 affect its incorporation, is based on impaired interaction of the mutant protein with one 
of its chaperones. Up to now, the protein domains within histone H3.3, which mediate 
histone-chaperone interaction, are not elucidated in detail, but as it has recently been shown 
for the chaperone DAXX, a region located within the H3.3 core domain is responsible for 
H3.3-DAXX interaction [119]. Therefore, it is quite unlikely that the identified H3.3 mutations, 
which are located at the tail of H3.3, interfere with chromatin incorporation due to aberrant 
histone-chaperone interaction.  
 
5.2 Global H3K27me3 Levels are reduced in K27M mutated pedGBMs 
Posttranslational modifications of the amino-terminal tail of histone proteins including 
methylation of lysine residues have been known for decades to directly alter chromatin 
structure and gene expression. While histone H3 methylation of lysine 4 (H3K4me3) or  
lysine 36 (H3K36me3) are hallmarks of actively transcribed chromatin, methylation of  
lysine 9 (H3K9me3) or lysine 27 (H3K27me3) are overrepresented at inactive genes. In 
recent years, the status and establishment of the key histone mark H3K27me3 has become 
of particular interest in cancer biology. This is based on the fact that several factors involved 
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in the establishment or maintenance of H3K27me3 are known to be mutated or deregulated 
in a multitude of human cancer entities [137, 180].  
The data depicted here also reports on the deregulation of H3K27me3 in K27M mutated 
pedGBMs. By using immunohistochemistry and Western blot analysis of primary tumor 
samples, it was demonstrated that pedGBMs, harboring the K27M mutation, show a global 
reduction of H3K27me3 levels (Figure 15). In contrast, G34R mutated tumors or tumors 
without H3F3A mutations exhibit high abundance of the H3K27me3 histone mark. As 
determined here, H3.3 protein in primary tumors is translated from transcripts of both H3.3 
producing genes H3F3A and H3F3B. Furthermore, biallelic expression of H3F3A in 
pedGBMs was confirmed. In summary, this leads to the assumption that in tumors with 
heterozygous H3F3A mutations the relative amount of mutated H3.3 protein is approximately 
25%. These findings together with the high abundance of canonical H3.1/H3.2, which is also 
detected by the H3K27me3 antibody, excludes the possibility that the global reduction of 
H3K27me3 is explained by the proportion of methionine containing H3.3, which never 
displays H3K27me3 (Figure 20). In conclusion, the data presented here reveals a strong 
dominant negative effect of K27M mutant H3.3 protein, which also impacts H3K27me3 
expression at the amino-terminal tail of other histone proteins including canonical H3.1/H3.2. 
 
 
Figure 20. Expression of mutant H3.3 in Primary Glioblastoma. Both alleles of H3F3A 
(heterozygous mutation of H3F3A depicted in red) and H3F3B are transcribed into mRNA in primary 
glioblastoma. Therefore, only 25% of total H3.3 protein in a H3F3A mutated tumor cell harbors the 
mutation. In humans, canonical H3.1/H3.2 is transcribed from 13 different genes into polycistronic 
mRNA. Via translation, large amounts of H3 protein are synthesized during S-phase to wrap up the 
duplicated DNA. Finally, the amount of mutated H3.3 protein within a tumor cell does not exceed more 
than 10% of total H3 protein.  
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In line with our results, a strong dominant negative effect on global H3K27me3 expression 
has previously been reported for mutant canonical H3, which replaces lysine 27 by an 
arginine residue (H3K27R) [181]. In this study, global H3K27me3 levels were found to be 
dramatically reduced (approximately by 75%) by overexpressing the K27R mutant in CP70 
human ovarian cancer cells. As in H3.3 mutated glioblastomas, gene expression is altered in 
CP70 cells overexpressing the H3 K27R mutant [181]. Furthermore, K27R overexpression 
lead to a significant reduction of global DNA methylation levels, resembling more the global 
DNA hypomethylation phenotype (CHOP) described in G34R mutant pedGBMs. 
Two independent studies, focusing primarily on histone function in the development of flies 
and mice, showed that overexpression of K27R mutated H3.3 but not K27R mutated 
H3.1/3.2 induced severe developmental defects [182, 183]. Expression of H3.3 K27R 
resulted in accumulation of pericentromeric transcripts, localization defects of the 
heterochromatin protein HP1 as well as defective chromosome segregation. In addition, 
Santenard et al. revealed decreased levels of H3K27me3 expression to about 65% in H3.3 
K27R overexpressing embryos. Besides that, H3K27me1 levels were decreased in the 
presence of K27R mutated H3.3, while other histone marks like H3K4me3 or H3K9me3 
remained unaffected [182]. Taken together, this work concludes that the establishment of 
heterochromatin (reflected by H3K27me3 levels) in the early developing embryo is disturbed 
by the presence of K27R mutant H3.3. However, regulation of heterochromatin formation is 
not restricted to the early developing embryo. Dysregulation of heterochromatin is also 
known to increase susceptibility to cancer by several mechanisms. Less heterochromatin 
formation reflected by reduced H3K27me3 levels, for example, would lead to aberrant 
expression of oncogenes and increased genomic instability. Consistently, reduced 
H3K27me3 levels are associated with unfavorable prognosis in breast, ovarian and 
pancreatic cancers [70, 184]. Besides H3K27me3, impaired establishment of other 
heterochromatic histone marks such as H3K9me3 also increase tumor risk due to 
chromosomal instability in vivo [185]. Based on unpublished whole-genome sequencing data 
of our laboratory, however, K27M mutated pedGBMs do not show a higher frequency of 
chromosomal aberrations compared to non-mutated tumor samples.  
Without reporting on heterochromatin formation, deregulated H3K27me3 levels have been 
demonstrated in a variety of human cancers. For most of these entities, H3K27me3 levels 
are altered due to genetic hits within the machinery responsible for H3K27me3 turnover. 
Elevated expression of the H3K27me3 establishing methyltransferase EZH2 is described in 
several human cancers including bladder, breast, gastric, lung and prostate cancer  
[186-189]. Here, the majority of tumors display activating mutations (e.g. Y641) or gene 
amplifications of EZH2. Other known mechanisms of EZH2 activation include the deletion of 
microRNA-101, which represents a negative regulator of EZH2 in prostate cancer [190]. 
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These findings together with the identification of deleterious mutations of the H3K27me3 
specific demethylase UTX (also known as KDM6A) point towards an oncogenic role of EZH2 
and the H3K27me3 histone mark. [191]. However, the identification of several mutations 
leading to loss of EZH2 methyltransferase activity and reduced H3K27 trimethylation indicate 
a dual role of this histone mark. In pedGBMs, the presence of additional mutations  
(e.g. EZH2 or UTX), which would explain decreased H3K27me3 expression, was excluded 
by analyzing whole-exome sequencing data of K27M mutated tumor samples [30, 47].  
As demonstrated here, the existence of deregulated H3K27me3 is a common event in 
human cancers. While for most of the entities the explanation is given by genetic hits in the 
H3K27me3 establishing machinery, the mechanism of H3K27me3 reduction by K27M mutant 
requires further investigation. One hypothesis about the mechanism of K27M induced 
reduction in H3K27me3 is based on the structural similarities between monomethylated 
lysine and its substituent methionine. The highly hydrophobic amino acid methionine 
represents the closest natural mimic of monomethylated lysine as it holds a terminal methyl 
group (Figure 21A). For this reason, methionine has already been used in other studies to 
imitate constitutively monomethylated lysine within H3 histone proteins [192]. Although the 
consequences of monomethylated H3K27 are discussed controversially, H3K27me1 is an 
essential intermediate in the establishment of H3K27 di- and trimethylation by the PRC1/2 
complexes. Thus, the K27M mutant H3.3 protein could function as a permanently bound 
substrate due to the fact that the addition of a second methyl group to the sulfur atom of 
methionine is chemically not possible. In doing so, the K27M bound PRC1/2 complex is not 
able to methylate other H3 histones leading to a successive reduction of H3K27me3 levels.  
 
 
Figure 21. Chemical Structure of (modified) Amino Acids. (A) The highly hydrophobic amino acid 
methionine structurally resembles mono-methylated lysine as both complexes hold a terminal methyl 
group (framed). (B) Dimetylated arginines exist in symmetric (SDMA) or asymmetric conformation 
(ADMA) displaying differences in the linkage of the second methyl group (framed). (C) The amino acid 
valine structurally resembles dimethylated arginine based on the two terminal methyl groups. 
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A second potential mechanism of H3K27me3 downregulation via K27M mutant H3.3 is 
based on the maintenance model of the H3K27me3 histone mark during cell division [99, 
193]. All controversially discussed models for the inheritance of histone methylation marks 
(reviewed in [70]) share one general feature: In order to preserve cellular identity, epigenetic 
marks including the repressive H3K27me3 mark, have to be transmitted to the next cell 
generation. Thus, the status of K27 methylation in the nucleosome at a respective genomic 
locus is copied to the daughter cell. Incorporated K27M mutant H3.3 protein, which is always 
devoid of methylation, would propagate the transmission of unmethylated lysine 27 to the 
daughter cell. If so, one would also assume that the effect of H3K27me3 downregulation is 
increasing over time because H3K27me3 needs to be diluted out with every round of cell 
division.  
As demonstrated here, the K27M induced downregulation of the crucial epigenetic mark 
H3K27me3 was successfully recapitulated in vitro (see Figure 16). Overexpression of K27M 
mutant H3.3 in HEK293T and SF188 glioblastoma cells for 15 passages led to strongly 
decreased H3K27me3 levels. Since this phenotype was not detectable at earlier time points, 
it becomes apparent that H3K27me3 reduction progresses over time and is dependent on 
several rounds of cell divisions. Recently, Turcan et al. reported on the successive 
establishment of the CIMP phenotype in immortalized astrocytes by overexpression of 
R132H mutant IDH1 [194]. In these experiments, comprehensive changes in genome-wide 
DNA methylation were induced after an extended time of in vitro cultivation of astrocytes for 
up to 50 passages. An independent study reported on the constantly accumulating 
downregulation of transgene expression as a result of increasing DNA methylation and 
successive establishment of repressive histone marks in long time cultured chicken erythroid 
cells [195]. Thus, both studies consistently indicate that reshaping of the epigenome largely 
depends on extended time periods.  
With respect to differential gene expression in K27M mutant primary pedGBMs, one should 
take into account that the presence of methionine at K27M mutant H3.3 also abolishes 
acetylation of this residue. H3K27 acetylation represents an epigenetic mark, which is 
directly implicated in the regulation of gene transcription [81, 196]. Acetylated H3K27 marks 
active enhancer regions, which are known to be highly enriched for H3.3 [197]. Western blot 
data presented here demonstrates that global H3K27ac levels are upregulated in tumors 
expressing K27M mutant H3.3. Loss of PRC2 activity, which results in reduced trimethylation 
of H3K27, has been described to result in a global increase in H3K27 acetylation [166, 167]. 
Thus, K27M induced downregulation of the repressive histone mark H3K27 might represent  
an essential step towards the establishment of transcriptional active chromatin via acetylation 
of H3K27.  
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5.3 Arginine 34 is posttranslationally modified at G34R mutated H3.3 
While one of the H3.3 mutations found in pedGBMs abolishes an essential site of PTM by 
eliminating lysine 27, the second mutation creates a potential new site for PTMs by the 
presence of arginine instead of glycine 34 at the tail of G34R mutated histone H3.3. Mass 
spectrometry data presented here confirms this new site of PTM at the tail of G34R mutated 
H3.3 by detection of dimethylarginine 34 (R34me2).    
In addition to the finding that arginine 34 is dimethylated at the tail of G34R mutant H3.3, this 
work also provides insights into potential functional consequences of the new PTM. As 
illustrated in Figure 17, R34me2 is associated with downregulation of K36 trimethylation in 
HEK293T cells and in the pediatric glioblastoma cell SF188. In general, trimethylation of 
lysine 36, which is located in close proximity to R34, is found at bodies of actively transcribed 
genes [198-200]. Notably, the crosstalk between arginine and lysine methylation is a wide-
spread phenomenon at the tail of histone proteins, which has been named as arginine/lysine-
methyl/methyl switches [201]. With regard to the histone tail of H3 (or H3.3), several 
arginine/lysine pairs are found including H3R2/H3K4, H3R8/H3K9 or H3R26/H3K27 (see 
also Figure 3). For all these arginine/lysine pairs, the arginine residue is located one or two 
amino acid position(s) upstream of the corresponding lysine residue. One of the best 
characterized arginine/lysine-methyl/methyl switches is the R2/K4 switch. For this switch it is 
well known that the methylation of arginine 2 by the protein arginine  
methyltransferase 6 (PRMT6) prevents the establishment of the K4me3 histone mark or vice 
versa [202, 203]. Trimethylation of lysine 4, which is established by the MLL1 complex, is 
(comparable to H3K36me3) an essential epigenetic mark in the establishment and 
maintenance of transcriptionally active chromatin [204]. Furthermore, the binding of H3K4 
effector proteins such as the demethylase KDM4A (also referred to as JMJD2A), which 
contains a methylation-specific tudor domain, is sensitive for R2 methylation [205]. 
Interestingly, KDM4A was also reported to act on methyl groups at lysine 36 of histone H3 
[206]. At the tail of G34R mutant H3.3, a similar conformation is generated by the presence 
of arginine at position 34. This conformation might represent the basis for a new 
arginie34/lysine36-methyl/methyl switch at G34R mutant H3.3. Remarkably, valine, the 
second amino acid, which was found to replace glycine 34 in G34V mutant H3.3 in some rare 
pedGBM cases, displays striking structural similarity to dimethylated arginine as it also holds 
two terminal methyl groups (Figure 21C).  
Based on our mass spectrometry data, it cannot be distinguished, whether dimethylarginine 
34 (R34me2) exists in symmetric (SDMA) or asymmetric (ADMA) conformation (Figure 21B). 
Since PRMTs show ADMA or SDMA specificity, the information about R34me2 conformation 
would be useful to narrow down the number of potential protein arginine methyltransferases 
(PRMTs) establishing R34 dimethylation. Although the number of PRMTs is constantly 
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growing, there are at least seven different PRMTs (PRMT1-4, 6, 8) catalyzing the production 
of asymmetric dimethyl arginine (ADMA) and two enzymes (PRMT 5, 7) producing the 
symmetrical variant [71]. Although numerous human cancers show aberrant PRMT 
expression, transcriptional deregulation of PRMTs has not been found in GBMs harboring a 
G34R mutation (Supplementary Figure 3). With the knowledge about the R34me2 
establishing PRMT, specific PRMT inhibitors could be used, as they were shown to possess 
pharmacological and therapeutic potential [207-211].  
In general, the histone tail of H3 has to adopt a conformation that fits into the substrate-
binding groove of effector proteins without steric clashes. The conformation of G34R mutant 
H3.3 that fits into the binding groove of the H3K36me3 establishing machinery, might not 
only be negatively influenced by the presence of methyl groups at R34 but also by the 
elimination of glycine at position 34 itself. Both glycine residues at position 33 and 34 
contribute to the overall flexibility of the H3 histone tail and consequently play an essential 
role in establishing the binding specificity of the H3K36 mediating demethylase KDM4A 
[212]. This H3K36 demethylase, which is also acting on H3K4, H3K9 and H4K20, is known to 
prefer small amino acid residues at the -2 position of the respective methylated lysine 
residue [206].   
 
5.4 Establishment of a mutant H3.3 in vitro Cell Culture System  
Pediatric glioblastomas expressing K27M or G34R mutated histone H3.3 are characterized 
by distinct gene expression profiles as well as different DNA methylation patterns [30, 48]. 
The work presented in this thesis was aiming at the establishment of an in vitro cell culture 
system, which can be used to recapitulate and characterize the molecular changes originally 
identified in H3.3 mutated pedGBMs.  
Initially, several primary cell lines established from freshly dissected H3.3 mutated pedGBMs 
were used to study the functional consequences of H3.3 mutations in vitro. These cell lines 
were thought to represent the ideal cell culture model since these cells express mutant H3.3 
from the endogenous H3F3A gene locus/gene promoter and include the genetic background, 
which in all likelihood contributes to the molecular phenotype of H3.3 mutated pedGBMs. 
After several months of in vitro cultivation, copy number data, which was produced as a by-
product of genome-wide DNA-methylation analysis, revealed complex genetic changes for 
most of these primary cell lines (Supplementary Figure 4). In addition, sequencing of the 
H3F3A genomic locus failed to detect the respective H3F3A mutation in our primary cell line 
originally established from a K27M mutated tumor. Moreover, other scientists are also 
reporting on the unsuccessful in vitro cultivation of K27M mutant cell lines (private 
communication with Yoon-Jae Cho). Most likely, H3.3 mutated cells undergo negative 
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selection, leading to clonal expansion of non-mutated cells of the primary tumor. As a result, 
primary cell lines originating from H3.3 mutated tumors were not available to molecularly 
characterize H3.3 mutations in vitro.       
Alternatively, overexpression of H3.3 mutants in previously established and well 
characterized glioblastoma cell lines was prioritized. As (nearly) all of the identified H3F3A 
mutations in pedGBMs were found to be monoallelic, expression of endogenous wildtype 
H3.3 seems to appropriately mimic the molecular phenotype detected in primary tumors. This 
is underlined by the presence of wildtype protein, which is produced from the second H3.3 
producing gene H3F3B that has never been found to be mutated in pedGBMs. Thus, one 
would expect that the expression of mutant H3.3 per se induces changes, which cannot be 
compensated by co-expressed wildtype protein (dominant negative effect).     
In order to determine, whether overexpression of mutant H3.3 induces similar effects on 
gene expression and DNA methylation in vitro, the pediatric glioblastoma cell line SF188 was 
used, since these cells carry TP53 mutations, which were frequently found to co-exist in 
pedGBMs. In contrary, the use of HEK293T cells provides the advantage of characterizing 
mutant H3.3 in a more isolated way without any masking or amplifying effect due to other 
genetic hits. At first glance, SF188 cells as well as HEK293T cells did not show any 
significant alterations in gene expression, DNA methylation, PTMs or growth characteristics 
upon mutant H3.3 overexpression (see 4.3). At a later time point, it emerged that the 
dominant negative effect on H3K27me3 expression induced by the K27M mutant was only 
detectable after several rounds of in vitro passaging (see 4.5). Since this work has shown 
that primary pedGBMs express higher levels of mutant H3.3 compared to lentivirally 
transduced cells, the amount of mutant H3.3 protein might be of key importance to 
successfully recapitulate the phenotype of H3.3 mutated pedGBMs at a certain time point. 
Since ectopically expressed H3.3 has never been found to result in similar abundance of 
exogenous H3.3 compared to the endogenous protein, the combinatorial knockdown and 
overexpression approach described in 4.4 might help to induce the effects caused by mutant 
H3.3 at earlier time points [164, 213]. Currently, the investigation of cell lines overexpressing 
mutant H3.3 for at least 2 months as well as cells combining knockdown of endogenous H3.3 
and mutant H3.3 overexpression is ongoing and includes genome-wide gene expression and 
DNA methylation profiling. 
 
5.5 In vivo Tumorigenic Potential of mutant Histone H3.3 
After infection of target cells by a retrovirus, the RNA genome of the virus is reversely 
transcribed into DNA and integrated into the host’s genome. Due to this ability, retroviruses 
have been used intensively to shuttle genetic information into nearly any mammalian cell 
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type. By transfection of the avian sarcoma-leukosis virus-A derived vector RCAS into avian 
cells, infectious virus is produced, which is able to infect any cell type expressing the virus-
entry mediating Tv-a receptor on its cell surface. The experiments conducted here used 
genetically modified mouse strains expressing the Tv-a receptor under the control of the 
nestin promoter (Ntv-a) to specifically target neural progenitor cells in the brain of newborn 
mice. This experimental setup has already been used to study the impact of other genes of 
interest in gliomagenesis [156, 214, 215]. The tumorigenic potential of mutant H3.3 was 
investigated by overexpression of mutant H3.3 in the brain of neonatal Ntv-a mice with 
consideration of the respective injection site (K27M midline; G34R hemispheric). In a second 
round of experiments, overexpression of H3.3 was introduced together with a dominant-
negative variant of TP53 (dnTP53), which completely abrogates endogenous TP53 function 
[168]. While overexpression of mutant H3.3 alone was not sufficient to induce GBMs, the 
combination with dnTP53 resulted in brain tumors in one K27M, one G34R and one wildtype 
H3.3 overexpressing animal. This tumor distribution and the fact that all tumors were 
diagnosed at the same (early) time point suggest that impaired TP53 signaling was the major 
driving force of tumor induction. This is in line with published data showing that TP53 
deficiency is heavily increasing the susceptibility to spontaneous tumors of various origin 
including brain tumors [216, 217]. TP53 knockout mice will die due to cancer by the age of 10 
months with 100% penetrance [218-220]. The high frequency of pedGBMs showing H3.3 and 
simultaneous ATRX/DAXX mutations might indicate that additional hits in chromatin 
modifiers within this pathway are required to induce tumors in vivo. 
Targeting the respective cell of origin is of central importance to induce tumors in vivo. For 
H3.3 mutated pedGBMs, there is growing evidence that K27M and G34R mutated tumors 
are derived from different cells of origin, which is reflected by distinct tumor epigenomes. 
Moreover, both mutations are tightly linked to different tumor localization within the CNS and 
differential expression of well-known lineage markers like OLIG1/2 and FOXG1 [48]. In 
general, several cell types including neural stem cells and progenitor cells as well as 
astrocytes are discussed to represent the cell of origin of glioma [221]. Different genetic hits 
in quiescent neural progenitor cells have been proposed to specifically underlie the 
development of IDH1 mutated gliomas [222]. In conclusion, the induction of GBM by 
expression of mutant histone H3.3 might be decisively dependent on targeting the correct 
cell type, which gives rise to this deadly brain tumor. for malignant glioma and 
prospect tumor location in the CNS, and differential 
expression of the key neuronal lineage markers OLIG1/2 and FOXG1s for clinical advancements.p53 loss occurs. 
occurs. 
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Both mutations within the gene H3F3A coding for the replication independent histone variant 
H3.3 were shown to define distinct subgroups of pediatric glioblastoma, which are 
characterized by different genetic and epigenetic profiles. The molecular mechanisms 
leading to these defined genome-wide alterations are of particular relevance to develop new 
treatment options for patient suffering from this devastating brain tumor.  
The molecular characterization of H3.3 mutations presented in this thesis provides evidence 
that H3.3 mutated pedGBMs are characterized by altered chromatin/histone modifications, 
which show mutation specificity. While K27M mutated pedGBMs are characterized by low 
levels of H3K27me3 due to the dominant negative effect of the K27M histone, the level of 
H3K36me3 at the tail of G34R mutant H3.3 is diminished, potentially caused by the presence 
of the new posttranslational modification identified in close proximity at arginine 34 of G34R 
mutant H3.3.  
Future experiments concerning the K27M mutant should aim at the molecular mechanism of 
K27M induced H3K27me3 reduction. As a multitude of human cancers is characterized by 
dysregulation of the H3K27me3 establishing methyltransferase EZH2 and the PRC2 
complex, localization of EZH2, its enzymatic activity and binding affinity to K27M mutant H3.3 
should be investigated in more detail. In order to do so, co-IP experiments using modified 
synthetic peptides are currently conducted to determine the binding affinity of EZH2 to K27M 
mutant H3.3. Genome-wide DNA methylation analysis and gene expression profiling of 
K27M transduced cell lines together with H3K27me3 ChIP-Seq data of primary tumors 
and/or K27M overexpressing cell lines will further enhance our knowledge about the K27M 
induced epigenetic changes.      
With respect to G34R mutated H3.3, the relationship between arginine 34 methylation and 
lysine 36 trimethylation needs further investigation. Therefore, mass spectrometry of primary 
tumor samples was initiated to dissect the pattern of PTMs at G34R mutant proteins. 
Furthermore, one should aim at the identification of R34me2 epigenetic readers by 
performing pulldown assays using unmodified and modified synthetic peptides of G34R 
mutant H3.3. In parallel, these co-IP experiments potentially lead to the identification of the 
R34me2 establishing protein arginine methyltransferase.  
The establishment of in vitro cell culture models, which mimic the transcriptomic and 
epigenetic changes of H3.3 mutant pedGBM, is of particular importance. These in vitro 
models are desperately needed to make the next step and translate the molecular findings of 
mutant H3.3 into clinical settings. Comprehensive drug screening assays on in vitro and/or in 
vivo models will aim at the identification of compounds targeting H3.3 mutated tumor cells 
with high specificity.  
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Currently, the screening of additional primary cell lines of H3.3 mutated tumors is ongoing, to 
support additional in vitro experiments.  
In conclusion, this thesis provides innovative insights into the genetic and epigenetic 
changes induced by mutant histone H3.3. In nearly 50% of pediatric glioblastomas, a genetic 
lesion within the H3F3A gene reshapes the epigenome of the tumor including DNA 
methylation and histone modifications, which consequently results in aberrant gene 
activation/repression. Thus, H3.3 mutated pedGBMs are a disease of the (epi)genome.  
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Supplementary Figure 1. Expression of canonical Histone H3 in primary GBMs. Histone H3 
microarray expression data (Probe set 214522_x) of 81 pedGBM samples, which were grouped 
according to their H3F3A mutation status (WT: n=56; K27M: n=14; G34R: n=11). 
 
 
 
Supplementary Figure 2. Expression of H3K27me3 modifying Enzymes. Microarray expression 
data of 81 pedGBM samples grouped according to their H3F3A mutation status (WT: n=56; K27M: 
n=14; G34R: n=11). Messenger RNA expression is illustrated for the PRC2 core components EED 
(A), EZH1 (B), EZH2 (C), RBAP48 (D) and SUZ12 (E) as well as for the H3K27me demethylase UTX 
(F). Following probe sets were used: EED (209572_s_at), EZH1 (32259_at), EZH2 (203358_s_at), 
RBAP48 (210371_s_at), SUZ12 (212287_at) and UTX (203992_s_at). 
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Supplementary Figure 3. Expression of PRMTs in primary GBMs. Microarray expression data of 
81 pedGBM samples with known H3F3A mutation status (WT: n=56; K27M: n=14; G34R: n=11) are 
illustrated as box blots for PRMT1 (A), PRMT2 (B), PRMT3 (C), PRMT4 (D), PRMT5 (E), PRMT6 (F), 
PRMT7 (G), PRMT8 (H), PRMT9 (I), PRMT10 (J) and PRMT11 (K). Following probe sets were used: 
PRMT1 (206445_s_at), PRMT2 (202098_s_at), PRMT3 (213320_at), PRMT4 (CARM1) 
(212512_s_at), PRMT5 (217786_at), PRMT6 (223275_at), PRMT7 (219408_at), PRMT8 (230839_at), 
PRMT9 (FBXO11) (222119_s_at), PRMT10 (228536_at) and PRMT11  (FBXO10) (227222_at).  
 
 
 
 
Supplementary Figure 4. Genomic Aberrations in H3.3 mutated Cell Line 10-801. The cell line  
10-801 was derived from a G34R mutated pedGBM displaying several genomic aberrations (top). 
After several month of in vitro cultivation, numerous new genetic abnormalities are detectable 
(bottom).    
